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ABSTRACT

Extended Maternal and Paternal Hereditary Risk for Alzheimer’s Disease Examined by
Sex in a Sample of Community Dwelling Older Adults in Cache County, Utah
by
Elizabeth K. Vernon, Doctor of Philosophy
Utah State University, 2021

Major Professor: Dr. JoAnn T. Tschanz
Department: Psychology
More than 12.7 million Americans are expected to develop Alzheimer’s Disease
(AD) by 2050. Identified risk factors for AD include advanced age, female sex, family
history, the presence the Ɛ4 allele of the apolipoprotein E (APOE) gene, and vascular risk
factors and conditions. Differential effects by sex appear among some of these risk
factors, however, sex differences have not been well-studied among others. This project
examined sex differences in the association between family history of AD, direct
maternal and paternal lineage of AD, parental longevity, and potential modifying effects
of cardiovascular risk factors and conditions in the risk for AD in a single population.
This project used extant data from the Cache County Study on Memory in Aging
(CCSMA) of 5,092 older adults, enriched with data from Medicare claims and death
certificates through the Utah Population Database. The results showed that having a firstdegree relative with AD was associated with a 58% increase in AD in males, Odds Ratio
(OR)= 1.58, p= .003, and a 66% increase in risk in females, OR= 1.66, p= <.001. In
females, a direct maternal but not paternal lineage of AD was associated with a 56%
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increased risk for AD, OR= 1.56, p=.005, whereas in males there was a trend, where
having both direct maternal and paternal lineages of AD were associated with a 51.3%
lower risk of AD, OR=0.487, p = .054. A history of maternal or paternal exceptional
longevity was not associated with AD risk in females. In contrast, males who were APOE
Ɛ4 carriers and with a history of exceptional maternal longevity were at 3-fold greater
risk of AD than those males with neither risk factor, OR= 3.15, p= .020. Interestingly,
males had 11% reduced risk for AD with a history of both exceptional maternal and
paternal longevity, OR= 0.894, p=.041. With respect to vascular factors and interactions
with family history, females with a history of congestive heart failure (CHF) and direct
paternal lineage of AD were at a 2-fold increased odds of AD, OR= 2.26, p= .013,
compared to females with neither risk factor. Those with a history of CHF were at an 11fold increased risk for AD, OR= 11.15, p=<.001. For males, there were no interactions
between family history of AD and vascular risk factors and conditions. Amongst both
females and males, several vascular factors or conditions were associated with increased
risk of AD, for instance, cerebrovascular accident and CHF for both females and males,
and hypertension and high cholesterol/triglycerides/atherosclerosis in males only.
Notably, a history of myocardial infarction in females was associated with lower risk of
AD. Overall, this study highlights the increased risk of AD among those with a positive
family history of AD in first-degree relatives, and sex differences in maternal or paternal
lineage, and vascular risk factors and conditions. Further research is needed to elucidate
the mechanisms underlying the above associations to develop potential preventive
interventions relevant to each sex.
(151 pages)
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PUBLIC ABSTRACT

Extended Maternal and Paternal Hereditary Risk for Alzheimer’s Disease Examined by
Sex in a Sample of Community Dwelling Older Adults in Cache County, Utah
Elizabeth K. Vernon

More than 6 million Americans are living with Alzheimer’s Disease (AD) and this
number is expected to rise and surpass 12.7 million individuals by the year 2050.
Currently there is no cure for the disease and prior research has focused on prevention by
identifying risk factors. Known risk factors associated with AD include older age, female
sex, genetics, family history of AD, genotype of the apolipoprotein E (APOE) gene, and
vascular risk factors (e.g., cholesterol, hypertension) and conditions or events (e.g., CHF,
stroke). The effects of many of the above risk factors have differed in men and women,
but few studies have examined how family history of AD, direct maternal or paternal
lineage of AD, parental longevity, and cardiovascular risk factors and conditions might
influence risk for AD differently for men and women. This project analyzed existing data
from a population-based longitudinal study, the Cache County Study on Memory in
Aging (CCSMA), that included permanent residents of Cache County, Utah who were
aged 65 years or older in 1995. The study’s data were enriched through additional data
obtained for extended family history and Medicare claims and death certificates that were
made available through data linkage with the Utah Population Database. The original
study ran from 1995-2007, but with the additional Medicare claims and death certificates,
identification of AD related outcomes and risk factors were extended to 2019. The aim of
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this current study was to examine whether the risk for AD differed between men and
women with regards to family history of AD, maternal and paternal lineage of AD,
longer-lived parents, and whether vascular health conditions affected these risks.
Results from this dissertation showed that having a first-degree relative (parents,
siblings, or offspring) with AD increased the risk for AD in men by 58%, Odds Ratio
(OR)= 1.58, p= .003, and women by 66%, OR= 1.66, p= <.001. Among women, direct
maternal but not paternal lineage of AD was associated with a 56% increased risk for
AD, OR= 1.56, p=.005, whereas in men, history of maternal or paternal lineage of AD
(above age 87) did not affect their risk of developing AD. Having a longer-lived mother
or longer-lived father was not associated with AD risk in women. However, men with a
history of a longer-lived mother and who had an APOE Ɛ4 positive genotype had three
times the risk of AD, OR= 3.15, p= .020. Men who had both a longer-lived mother and a
longer-lived father compared to men without had an 11% reduction in risk for AD, OR=
0.89, p=.041. In relation to cardiovascular conditions and risk in women, those with a
history of congestive heart failure (CHF) and a direct paternal lineage of AD had double
the risk of AD compared to those without, though those women with no paternal lineage
of AD were at an 11 times greater risk, OR= 11.15, p=<0.001. For men there were no
associations between family history of AD and cardiovascular conditions. Among both
men and women, several cardiovascular risk factors increased risk for AD. For instance,
men and women with a history of stroke or CHF had an increased risk for AD. Men with
a history of hypertension and high cholesterol/triglycerides/atherosclerosis were also at
increased risk of developing AD. Notably, women with a history of myocardial infarction
had a reduction in risk.
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Although this study is observational in nature and thus does not prove a direct
causal relationship between familial history and AD, it does support previous research
that found having a first-degree relative with AD regardless of sex increased the risk for
AD. The study also highlighted the importance of studying risk factors like family
history, separately for men and women. Thus, women with a maternal history of AD
were at greater risk than those with a paternal history of AD, but no such association was
found in men. Men were at slightly reduced risk for AD when having both longer-lived
parents and there were slight differences by sex in cardiovascular risk factors that
predicted risk for AD. The different results obtained for men and women have clinical
implications in monitoring for AD risk in older adults and suggest aggressive treatment
for vascular risk factors and conditions amongst women in particular, with CHF and
family history. Further research is needed to understand the underlying mechanisms with
how these risks vary in males and females.
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CHAPTER I
INTRODUCTION
Approximately 6.2 million Americans are living with Alzheimer’s Disease (AD)
and this number is expected to rise to more than 12.7 million individuals by the year 2050
(Alzheimer’s Association, 2021). Currently, there is no cure for the disease and one
priority has been on prevention (Alzheimer’s Association, 2021). Identified risk factors
associated with sporadic, late-onset AD include advanced age (Guerreiro & Bras, 2015),
female sex (Mielke et al., 2014), family history (Cannon-Albright et al., 2019), carrying
the apolipoprotein Ɛ4 allele (APOE Ɛ4; Farrer et al., 1997), and vascular risk factors and
conditions (Barnes & Yaffe, 2011). Among several of these risk factors, there appears to
be differential effects in males and females.
Females account for two-thirds of cases of AD in the US (Alzheimer’s
Association, 2021). Differences in longevity have been used to explain the differing rates
in males and females; however, some research suggests this does not fully explain the
disparity (Mielke et al., 2014). The underlying mechanism associated with sex
differences in AD risk remains unclear. One factor possibly contributing to this disparity
includes the maternal/paternal transmission of the disease to the offspring (Mosconi et al.,
2007; Mosconi et al., 2010).
A family history of AD is a risk factor for the disorder. Several studies have found
that a positive family history is associated with a 4-10 times increased risk of developing
AD (van Duijn et al., 1991; Fratiglioni et al., 1993). Having at least one first-degree
relative with dementia increases the risk by approximately 4-fold; with each additional
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affected first-degree relative, the risk further increases approximately 2-fold (van Duijn et
al., 1991; Fratiglioni et al., 1993). A recent study reported that extended family history
also was associated with risk of AD, and risk differed by sex of the affected parent
(Cannon-Albright et al., 2019). Cannon-Albright and colleagues (2019) found that having
a first-degree relative with AD increased the risk of AD, which exponentially increased
with each additional first-degree relative affected. In addition, the authors found sex
differences in the transmission of AD in second-degree relatives, with a greater increase
in risk found in the maternal familial line (Cannon-Albright et al., 2019). Several other
studies have also found varying risk associated with maternal and paternal transmission
of AD, with a stronger association in the maternal transmission (Honea et al., 2012;
Mosconi et al., 2007; Mosconi et al., 2010). Recent studies have found evidence of
significant AD biomarkers in those with a maternal family history compared to those
with a paternal family history or among those without a positive family history. The
associations in biomarkers included an increased deposition of Pittsburgh B Compound
(PiB) in the parietal, sensorimotor cortices, and precuneus of the brain (Honea et al.,
2012) and reduced glucose metabolism in the medial-temporal lobe, parietotemporal
region, posterior cingulate, and frontal cortices (Mosconi et al., 2007). In cerebrospinal
fluid, reduced beta amyloid and increased tau/amyloid-beta ratio have been reported
(Honea et al., 2012). However, a large study of 1,220 older adults, found an association
with paternal but not maternal transmission of AD (Ehrenkrantz et al., 1999). It is unclear
what factors underlie these discrepant results, although sex of the proband, health-related
risk factors and genetic variables may contribute.
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The apolipoprotein E (APOE) gene has been associated with risk for developing
AD. Several studies have reported varying effects in males and females who carry the
APOE Ɛ4 allele. Specifically, many have found a greater risk of AD in female APOE Ɛ4
allele carriers compared to male carriers of the allele (Bretsky et al., 1999; Farrer et al.,
1997). However, males with two APOE Ɛ4 alleles also appear to be at greater risk of AD
than those males carrying one or no APOE Ɛ4 allele (Payami et al., 1996). This sex
difference may contribute to the differing rates of AD amongst males and females and
may contribute to discrepant results in family history studies.
As noted above, greater longevity is associated with increased AD risk (Guerreiro
& Bras, 2015). Sex differences also appear in longevity, with females living longer than
males (Center of Disease Control [CDC], 2017), and thus, this factor may contribute to
sex differences in AD rates and discrepant family history studies (Passarino et al., 2016).
Exceptional longevity (generally defined as aging beyond age 85) however, is associated
with lower risk of AD (Jorm & Jolley, 1998), delayed onset of cognitive decline
(Andersen et al., 2012), as well as reduced morbidity (Andersen et al., 2012; Westendorp
et al., 2009). Offspring of exceptionally long-lived parents have shown reduced
cardiovascular health conditions (Westendorp et al., 2009) as well as reduced risk of
developing AD (Lipton et al., 2010). Little research has examined how parental longevity
relates to sex differences in AD risk or differences in maternal or paternal transmission.
As noted above, exceptional parental longevity is associated with reduced
morbidity in offspring (Westendorp et al., 2009) and in particular, cardiovascular
conditions (Westendorp et al., 2009). Cardiovascular risk factors and conditions, which
have been associated with increased risk of developing AD, include hypertension,
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hypercholesterolemia, low physical activity, diabetes mellitus, stroke, obesity, and
metabolic syndrome (de Bruijn & Ikram, 2014). There are sex differences in the type or
form of cardiovascular disease (CVD) as well. Females appear to have greater risk for
developing CVD through microvascular disease, whereas males show greater risk with
obstructive coronary disease (Bairey-Merz et al., 2006). In AD, significant microvascular
changes have been observed in the brain and these changes have been associated with
more severe AD symptomology (De la Torre, 2002). In addition, studies have found that
compared to males, females are at greater risk for complications due to diabetes mellitus
such as myocardial infarction, depression, and coronary heart disease (Kautzky-Willer et
al., 2016). These conditions have also been associated with increased risk for AD (Barnes
& Yaffe, 2011). Taken together, the unique cardiovascular profile in females may put
them at higher risk for AD compared to males. However, few studies have investigated
the type of coronary heart disease and risk for AD in either males or females.
The above literature discusses several modifiable and non-modifiable risk factors
of AD. Interesting associations with AD are noted for familial history of AD in maternal
vs. paternal lines, the role of exceptional longevity, the overall lower risk of
cardiovascular morbidity with exceptional longevity and sex differences in
cardiovascular disease risk. These studies have been conducted in various samples and
together identify important risk factors for AD. However, sex differences in the role of
family history, exceptional longevity and cardiovascular risk factors and conditions have
not been well studied. This project examined the association between direct maternal and
paternal lineage of AD and AD risk and examined sex differences in risk in a single
population sample. Additionally, parental longevity and cardiovascular risk factors and
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conditions were examined as potential modifiers of these relationships. This project used
extant data from the Cache County Study on Memory in Aging (CCSMA), a longitudinal
population-based study of antecedents of dementia and cognitive decline in a sample of
5,092 older adults. Linkage of the CCSMA with the Utah Population Database (UPBD)
allowed for enrichment of the available data by extending data obtained from other
sources to include extended family history information and through further linkage with
Medicare claims data, additional health-related data (https://rge.utah.edu/).
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CHAPTER II
REVIEW OF THE LITERATURE
Risk Factors for Alzheimer’s Disease
It is estimated nearly 12.7 million individuals in the United States will be living
with Alzheimer’s Disease (AD) by the year 2050 (Alzheimer’s Association, 2021). There
is no cure for the disease, and efforts have focused on identifying risk factors for primary
prevention (Alzheimer’s Association, 2021). Several risk factors for AD have been
identified and include mid-life hypertension, high cholesterol, diabetes mellitus, diet, and
sleep disturbance (Barnes & Yaffe, 2011). The greatest risk factor appears to be advanced
age, with those living longer exhibiting greater risk (Alzheimer’s Association, 2021).
Family history is also a strong predictor of AD, reflecting both genetic transmission as
well as lifestyle traditions or psychosocial factors "handed down" across generations
(Cannon-Albright et al., 2019). Sex differences have been reported in AD, with females
exhibiting greater risk than males (Nebel et al., 2018). However, the underlying
mechanisms contributing to this disparity (e.g., greater longevity in women, differences
in hormonal changes in late life, and various lifetime psychosocial factors) remains
unclear. This project examined select factors that may contribute to sex differences in AD
risk.

Alzheimer’s Disease in Females
AD is more prevalent among females where it accounts for approximately twothirds of all cases in the US (Alzheimer’s Association, 2021). Compared to males,
females are also twice as likely to receive a diagnosis of dementia after age 60 (Nebel et
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al., 2018). It is estimated that after the age of 45, the lifetime risk of developing AD in
females is approximately 20%, compared to approximately 10% in males (Nebel et al.,
2018).
Many studies have investigated sex differences in the risk for AD in advanced
age. The Cache County Study on Memory in Aging (CCSMA) found modest differences
in incidence rates of AD between males and females prior to age 78, after which the
incidence of AD increased two-fold (with age) in females compared to males. Incidence
rates for both males and females declined with age in the mid-to-late 90s and beyond
(Miech et al., 2002). Similarly, Roberts and colleagues (2012) found conversion rates
from Mild Cognitive Impairment (MCI) to AD did not significantly differ between males
and females between the ages 70-79. After the age of 80, however, higher rates of
conversion were found in females (Roberts et al., 2012). Beam and colleagues examined
the incidence rate of AD in 16,926 females and males in The Swedish Twin study. They
found the incidence rate to be greater in females after age 85 for AD and all-cause
dementia (Beam et al., 2018). However, other studies have failed to report a sex
difference in AD incidence. Hebert and colleagues (2001) examined incidence of AD in a
population of 3,089 older adults, aged 65 and older, who were dementia free at baseline
from the Established Populations for Epidemiologic Study of Elderly (EPESE) Project of
East Boston. Six hundred forty-two individuals developed dementia over three years. The
authors used life tables to estimate incidence for males and females for a hypothetical
sample of 100,000 for each sex. They found that age-specific incidence of AD did not
differ in males and females (Hebert et al., 2001). In addition, they found that the
prevalence of AD did not differ by sex nor did mortality among those with AD. The
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authors concluded that the excess number of females with AD was due to longevity rather
than other sex-specific factors (Hebert et al., 2001). Similarly, a study examining 1,236
community dwelling adults aged 55 and older, from the Baltimore Longitudinal Study of
Aging (BLSA), found no significant difference in AD incidence rates between males and
females over a 13-year follow-up period (Hebert et al., 2001). However, there was a trend
for females to have a 10% higher incidence of AD than males (p=.065) of similar age and
educational attainment (Kawas et al., 2000). The studies above present mixed results in
the incidence of AD for males and females, though differences in the ages of the samples
and duration of follow-ups may contribute to discrepant findings.
Sex differences have also been observed in the prodromal stage of dementia, or
MCI (Csukly et al., 2016). Several forms of MCI have been identified: amnestic MCI in
which memory loss is predominant and non-amnestic MCI in which cognitive domains
other than memory are impaired (e.g., visuospatial abilities) (Csukly et al.,2016). In at
least one sample, males were found to have a higher prevalence rate of non-amnestic
MCI (20%) compared to females (10.9%; Roberts et al, 2012). In addition, females
appear to have greater MCI incidence rates in older ages than males (Roberts et al.,
2012). Non-amnestic MCI has been associated with higher conversion rates to non-AD
dementias, while amnestic MCI is considered a prodrome to AD (Petersen, 2004). Thus,
some of the sex discrepancies in AD rates at later ages may be explained in part by
greater prevalence of MCI in females at older ages, and possibly with males having
greater non-amnestic MCI.
Recent research suggests that hormonal changes in females in mid-to-late life also
may contribute to sex differences in AD risk (Mielke et al., 2014). Hormonal changes
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that accompany menopause include reduced estrogen levels, which have implications for
various physiological processes in the brain. For example, menopausal and
perimenopausal females have reduced brain glucose metabolism, increased development
of amyloid plaques, and reduced production of brain-derived neurotrophic factor (BDNF;
a protein that is integral to synaptic development and plasticity) (Mosconi et al., 2010)).
These changes have been postulated to contribute to the increased risk of AD amongst
females (Mielke et al., 2014). In addition, structural changes such as reduced gray matter
and white matter in areas of the brain associated with AD (e.g., the default mode
network) also have been associated with menopause (Mosconi et al., 2010). Furthermore,
hormone therapy, initiated near the onset of menopause is associated with a reduction in
risk for AD in females (Zandi et al., 2002; Whitmer et al., 2010), though clinical trials
have not borne conclusive results (Shumaker et al., 1998; Harman et al., 2005). While the
specific mechanisms are unclear, the above research suggests physiological changes in
relation to menopause in females that may also contribute to the sex differences in the
rates of the disease.

Family History of Alzheimer’s Disease, Maternal/Paternal
Transmission, and Sex Differences in AD Risk
Several studies have found increased risk of developing AD in those individuals
with a positive family history of the disease (van Duijin et al., 1991, Fratiglioni et al.,
1993; Cannon-Albright et al., 2019). A positive parental history of AD has been
associated with 4-10 times greater risk of developing AD or other dementias in the
proband (van Duijn et al., 1991; Fratiglioni et al.,1993). In a re-analysis of seven case
control studies by van Duijn and colleagues (1991), they found a 3.5-fold increased risk
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of AD for those with at least one first-degree relative with all-cause dementia (van Duijn
et al., 1991). In addition, they examined age of onset in relation to risk and found the
relative risk decreased with increasing age of onset. Van Duijn and colleagues (1991)
also found those with two or more first-degree relatives had more than seven times the
risk of developing AD (RR=7.5; van Duijn et al., 1991) than those without a family
history. Another study by Fratiglioni and colleagues (1993) examined the association
between first-degree relatives with all-cause dementia and risk for developing AD in a
case-control study. Ninety-eight cases and 216 controls were examined in a populationbased study in Stockholm. The authors found that having at least one first-degree relative
with all-cause dementia was associated with a 3.2-fold relative risk of developing AD
compared to those without a first-degree relative with dementia (Fratiglioni et al., 1993).
The above studies did not examine extended family history (e.g., second-or-higher degree
relatives) or sex differences amongst the proband.
A recent study by Cannon-Albright and colleagues (2019) examined extended
family history and sex differences associated with the risk of developing AD. They found
in state-wide death certificates of older adults in Utah, family history of at least one firstdegree relative doubled the relative risk of developing AD. The relative risk nearly
doubled beyond that (RR=3.98) with having two first-degree relatives; having four firstdegree relatives further increased the risk 14-fold (Cannon-Albright et al., 2019).
Furthermore, the authors found sex differences among maternal/paternal lines. Having a
first-degree male relative with AD was associated with a greater risk compared to having
a first-degree female relative with AD (Cannon-Albright et al., 2019). However, the
authors found evidence for increased maternal transmission of AD amongst second-
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degree relatives (i.e., mother’s brother; RR=1.58); paternal second-degree relative (i.e.,
father’s brother; RR=0.95) was not significant. The maternal association was only found
amongst analyses examining second-degree relatives and not those examining first- or
third-degree relatives. Other studies have reported a stronger association with maternal
transmission of risk for AD than paternal transmission for both male and female probands
(Honea et al., 2012; Mosconi et al., 2007; Mosconi et al., 2010).
A recent study by Honea and colleagues (2012) examined biomarkers of AD in
403 individuals with vs. without a family history of AD in a cross-sectional analysis of
participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study. The
participants were classified as having normal cognition, MCI, or AD. They found that a
maternal family history of AD was associated with increased uptake of Pittsburgh B
Compound (PiB; a biomarker reflecting beta amyloid deposition) in the parietal and
sensorimotor cortices and the precuneus areas of the brain in all participants, regardless
of cognitive status. (Note, the degree of PiB uptake did differ by cognitive status) (Honea
et al., 2012). Additionally, those with a maternal family history of AD had reduced
cerebrospinal fluid (CSF) amyloid-beta (Aβ) levels and increased tau/Aβ ratio, both
known biomarkers of AD, compared to participants with a paternal family history only or
no family history (Honea et al., 2012). Another study of cognitively normal older adults
found that those with a maternal family history of AD showed reduced glucose
metabolism in the medial-temporal lobe and parietotemporal, posterior cingulate, and
frontal cortices compared to those with a paternal family history (Mosconi et al., 2007).
In a follow-up to this study, the authors found that cognitively normal individuals at
baseline with a maternal family history had progressive reductions in brain glucose
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metabolism over a two-year period compared to those with a paternal or negative family
history (Mosconi et al., 2010). These studies suggest greater AD pathology in those with
a maternal family history of the disease. In contrast, however, Ehrenkrantz and
colleagues (1999) found in a sample of 1,220 individuals, there was no evidence of
maternal transmission of the disease but there was evidence of paternal transmission of
AD. While this is a single study that does not support a maternal transmission, the study
consisted of a large sample size and an extensive longitudinal follow-up period (up to 15
years) completed by the Mount Sinai Alzheimer’s Disease Research Center.
In summary, several studies have reported the significance of a maternal family
history of AD to be significant for AD risk, although at least one large study reports the
importance of paternal family history. The above studies differed in sample size,
geographic locations (lifestyle and cultural factors), determination of dementia diagnosis,
and method of determining family history. Not examined was whether maternal/paternal
transmission of AD varied by the sex of the proband or by genetic factors.

Sex Differences in Apolipoprotein Ɛ4 Allele
Carriers in Risk for Alzheimer’s Disease
Sex differences also appear in relation to the genetic risk associated with the
apolipoprotein E (APOE) gene. Several studies have found a four-fold increased risk of
developing AD amongst female APOE Ɛ4 carriers compared to female non- Ɛ4 carriers
(Bretsky et al., 1999; Farrer et al., 1997; Payami et al., 1996). By contrast, male APOE Ɛ4
carriers reportedly exhibit little-to-no risk compared to male non- Ɛ4 carriers (Bretsky et
al., 1999), though one study reported that males carrying two copies of the APOE Ɛ4
allele appeared to be at 5-fold greater risk compared to those without an APOE Ɛ4 allele
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(Payami et al., 1996). A study by Corder and colleagues (2004) examined 5,000 autopsies
of individuals between 25-96 years of age and found an interaction between age, sex, and
APOE Ɛ4 status. They found that middle-aged female APOE Ɛ4 carriers had more brain
regions affected by AD pathology than male APOE Ɛ4 carriers. In addition, they found,
that among AD patients, female APOE Ɛ4-allele carriers (one or 2 copies) presented at
autopsy with more amyloid plaques and neurofibrillary tangles compared to all noncarriers and male APOE Ɛ4 allele carriers in earlier Braak stages (a staging system of
Alzheimer’s neuropathology). However, the sex difference in amyloid plaques and
tangles were not evident in later Braak stages (Corder et al., 2004). In addition, Fleisher
and colleagues (2005), in a sample of cognitively normal adults, found greater loss of
hippocampal volumes in female APOE Ɛ4 carriers compared to male APOE Ɛ4 carriers.
Other differences in the brains between the sexes have been found in cortical thickness
and volumes among cognitively normal adults, with a more pronounced loss in female
APOE Ɛ4 carriers than in male Ɛ4 carriers (Liu et al., 2010). In summary, several studies
suggest sex differences in AD risk by APOE genotype. However, not explored are
whether familial transmission (maternal or paternal lines) further influence AD risk
beyond the apparent sex-specific risk of APOE genotype. Additionally, overall family
longevity has not been examined in prior studies.

Differences in Parental longevity and Risk for Alzheimer’s Disease
As noted earlier, advanced age is the number one risk factor for AD (Guerreiro &
Bras, 2015), though in extreme old age, risk appears to decline (Andersen et al., 2012;
Miech et al., 2002). Studies report a 2-fold increase in risk for AD for both males and
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females (or regardless of sex) for each year after the age of 65 (Jorm & Jolley, 1998).
Longevity is related to both genetic and environmental factors (Passarino et al., 2016)
and exceptional longevity (generally considered over age 86 is associated with reduced
morbidity including reduced cognitive decline (Andersen et al., 2012). A study by
Andersen and colleagues (2012) examined nonagenarians (87-99 years of age),
centenarians (100-104 years of age), semicentenarians (105-109 years of age), and
supercentenarians (110 and above years of age) and prevalence of at least one age related
disease (cardiovascular disease, chronic obstructive pulmonary disease, dementia,
diabetes mellitus, and stroke). The authors found delayed onset of at least one of the
above age-related disease in those with exceptional longevity (aged 87 and older)
compared to controls (those between 47-87 years of age without a family history of
exceptional longevity) (Andersen et al., 2012). They also found significantly reduced
hazard of morbidity in all advanced age groups compared with controls. The authors
suggest the reduced hazards with extreme old age indicate compression of morbidity,
meaning reduced risk of age-related diseases at the upper age ranges of the human life
span (Andersen et al., 2012). In addition, with respect to cognitive functioning in this rare
sample, older age was associated with a delay in the onset of cognitive difficulties
(Andersen et al., 2012). Interestingly, males outperformed females on all cognitive tests
at all ages (Andersen et al., 2012), which is not a pattern seen at younger ages
(Sundermann et al., 2016). Similarly, Westendorp and colleagues (2009) examined risk
of morbidity among familial nonagenarians (two siblings aged 90 and above), sporadic
nonagenarians (one individual aged 90 and above), and the offspring of both groups.
They found amongst nonagenarian siblings, there was a reduced risk of morbidity (41%)
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compared to sporadic nonagenarians (Westendorp et al., 2009). The authors further
examined comorbidity rates in the offspring of the familial and sporadic nonagenarians.
They found that compared to offspring of sporadic nonagenarians, offspring of sibling
nonagenarians had lower prevalence of myocardial infarction (2.4% vs. 4.1%), diabetes
mellitus (4.4% vs. 7.6%), hypertension (23.0% vs. 27.5%) and use of cardiovascular
medications (23.0% vs. 28.9%) (Westendorp et al., 2009). Lipton and colleagues (2010)
examined exceptional parental longevity and risk of developing AD. They found in a
sample of community-dwelling, non-demented older adults (at baseline) followed for 23years, that those with a parent living longer than age 95 were at 43% reduced risk of
developing AD compared to those whose parents died prior to age 95 (Lipton et al.,
2010). Thus, it appears that parental exceptional longevity is inversely related to risk of
AD.
The above literature review highlights several non-modifiable (e.g., family
history, APOE allele carrier status, parental longevity) risk factors that may in part
underlie the sex differences in AD risk. A family history of AD is associated with
increased risk of developing the disease and this association has been found in both
immediate and extended family histories (Cannon-Albright et al., 2019), with differences
depending on the sex of the affected relative (i.e., male first-degree relative increased the
risk of developing AD in the proband compared to a female first-degree relative) and
opposite effects amongst affected second-degree relatives (Cannon-Albright et al., 2019).
While this study had strengths in the ability to examine extended family histories, a
significant limitation was the reliance on death certificates for ascertainment of AD
where dementia is often missed as a cause of death (Frecker et al., 1995; Raiford et al.,
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1994). Many studies report greater risk of AD with maternal transmission (Honea et al.,
2012; Mosconi et al., 2007; Mosconi et al., 2010, and an association with AD biomarkers
in persons without dementia (Honea et al., 2012; Mosconi et al., 2007; Mosconi et al.,
2010). However, at least one large study found greater risk of AD amongst probands with
a paternal history (Ehrenkrantz et al., 1999). Sex differences are also found related to
APOE genotype, with female APOE Ɛ4 carriers being at greater risk for AD than their
non-Ɛ4 counterparts (Bretsky et al., 1999; Farrer et al., 1997; Payami et al., 1996).
Amongst males, APOE Ɛ4 homozygotes are at greater risk for AD (Payami et al., 1996).
While in general, advanced age is a risk factor for AD, exceptional longevity is inversely
related to AD risk (Andersen et al., 2012). At least one study found exceptional longevity
was associated with reduced risk of AD in offspring (Lipton et al., 2010). In the literature
published to date, it is unclear how the above factors (family history, APOE genotype,
and parental longevity) collectively or in interactions influence AD risk in males and
females. Furthermore, it is unknown how these factors are associated with modifiable
vascular risk factors for AD. In the section below, modifiable cardiovascular risk factors
are discussed in relation to sex differences.

Modifiable Health-Related Cardiovascular
Risk Factors for Alzheimer’s Disease
A large number of observational studies have identified several modifiable risk
factors for AD, including cardiovascular disease (CVD), diabetes mellitus, metabolic
syndrome, and obesity (Barnes & Yaffe, 2011). In addition, hypertension,
hypercholesterolemia, low physical activity, atrial fibrillation, stroke, and nonMediterranean diets (the Mediterranean diet is high in vegetables, low in unsaturated
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fatty acids) have also been associated with the development of AD pathology in the brain
(de Bruijn & Ikram, 2014). In a meta-analysis, Barnes and Yaffe (2011) concluded that
mid-life hypertension (OR=1.61), mid-life obesity (RR=1.6) and diabetes (RR=1.39)
contributed to a significant portion of the cases of AD worldwide (Barnes & Yaffe,
2011). CVD interactions with APOE have also been reported in AD risk (Barnes &
Yaffe, 2011). Further, a Swedish study of identical and fraternal twins found that nonstroke CVD was associated with a two-fold increased risk of developing AD in those
individuals carrying the APOE Ɛ4 allele; noncarriers of the Ɛ4 allele were not at greater
risk. The study also found that the twin with dementia was approximately two times more
likely to have CVD than the twin without dementia (OR=1.86; Eriksson et al., 2010).
Gottesman and colleagues (2017), found in a bi-racial sample of 15,744 black and white
older adults, those with a history of midlife diabetes, prehypertension (systolic pressure =
120-139 mm Hg and diastolic pressure = 80-89 mm Hg), and hypertension (systolic
pressure=140 and above and diastolic pressure=90 and above) were at a 39% increased
risk of developing AD in later life. compared to those without these conditions. Diabetes
was associated with a 77% increased risk of AD (Gottesman et al., 2017). Not well
studied however, is whether the association between AD and CVD varies by sex, a
potentially important question given the sex differences in the development of CVD
(Kautzky-Willer et al., 2016). Females for example, appear to be at greater risk of
developing CVD through microvascular disease (involvement of small vessels) whereas
males appear at greater risk of CVD due to obstructive coronary heart disease (BaireyMerz et al., 2006). Of note, microvascular changes in the brain have been associated with
symptomatic AD and have been found patients with AD at autopsy (De la Torre, 2002).
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By contrast, obstructive coronary heart disease has not been specifically studied as a risk
factor for AD. The underlying differences in the cause of CVD between males and
females may suggest that females are more susceptible to AD (through microvascular
changes). Kautzky-Willer and colleagues (2016) also found that compared with males,
females have greater risk for complications from diabetes, including myocardial
infarction, depression and coronary heart disease, all of which have been identified as
risk factors for AD (Barnes & Yaffe, 2011). Depending on the underlying cause of
cardiovascular disease, sex may be an important consideration. Despite the large number
of studies examining vascular risk factors and AD, few have examined sex differences in
AD risk.
The above literature review summarizes a plethora of studies of risk factors for
AD, particularly, family history, APOE genotype, advanced age, exceptional longevity,
and modifiable cardiovascular factors. Some studies have examined sex differences, but
few have attempted to study whether the above factors have similar associations in males
and females or examined interaction amongst risk factors. The current project examines
sex differences in the associations between extended familial maternal and paternal
lineage of AD and interactions with parental longevity and cardiovascular risk factors and
conditions within a single population. The Cache County Study on Memory in Aging
(CCSMA) has conducted dementia surveillance in a sample of 5,092 older adults for up
to 12 years. Linkage with demographic and health databases through the Utah Population
Database (UPDB) allowed an enrichment of outcomes and risk factors including
extended family history of AD and health data. The research questions/aims are:
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1. Does extended (4-generations) family history of AD and risk for AD vary by
the sex of the proband?
2. Does direct maternal or paternal lineage of AD differentially affect risk for
AD and does this differ by sex of the proband?
3. Is parental (maternal and/or paternal) longevity associated with risk for
developing AD and does this risk vary by sex of the proband?
4. As an exploratory aim, examine whether cardiovascular risk factors and
conditions are associated with direct maternal or paternal lineage of AD and
risk of AD in the proband, and examine if associations vary by sex.
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CHAPTER III
METHOD
Study Design
This study is a secondary data analysis of an extant dataset from the Cache
County Study on Memory in Aging (CCSMA), supplemented with linked datasets to the
Utah Population Database (UPDB; Norton et al., 2016), including Medicare Claims data
(Hanson, Smith, & Zimmer, 2015). CCSMA was a longitudinal study with data collection
that began in 1995 and ended in 2007. It consisted of four triennial waves to examine
antecedent risk factors of cognitive decline and dementia (Miech et al., 2002). All but one
of the 5,092 participants of the CCSMA have been linked to the UPDB, a data repository
that contains over seven million records, including the genealogical records of the
founders of Utah and their descendants (Norton et al., 2016). The UPDB has been further
linked to Utah birth and death certificates (Cannon-Albright et al., 2019) and includes
primary and contributing causes of death. Via the UPDB, health data from Medicare
Claims from approximately 1992 – 2012 are available for the majority of the CCSMA
participants (Hanson et al., 2015; Norton et al., 2016). The Medicare claims data utilize
the International Classification of Diseases (ICD) version 9 for the present study (Hanson
et al., 2015). This study used data for those participants in CCSMA who have a deep
genealogical history in the UPDB (two prior generations of information beyond the
proband) and who have Medicare claims data. The study design and procedures of the
CCSMA have been described previously (see Miech et al., 2002), and are briefly
summarized below.
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The Cache County Study
Five thousand six hundred and seventy-seven older adults met eligibility criteria
for the CCSMA in 1995, which included being a permanent resident of Cache County,
Utah and over the age of 64. Approximately 90% (5,092) enrolled. The study consisted of
four triennial waves, which included a multi-stage dementia screening and assessment
protocol. Baseline cognitive screening and risk factor interviews were conducted at the
participant’s place of residence. Cognition was assessed using the modified Mini-Mental
Status Examination (3MS; 100-point measure; Teng & Chui, 1987) which was adapted
for the study (Tschanz et al., 2002). A proxy interview was given to those participants
who scored below 60 on the 3MS or could not complete the 3MS, scored below 15 (out
of 20) on orientation questions, or were otherwise deemed unreliable (Breitner et al.,
1999). The proxy interview included a rating of the subject’s cognitive status using the
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE; Jorm & Jacomb,
1989). Participants who scored below a cutoff of 87 on the 3MS or above a 3.27 on the
IQCODE were sent to the second stage, a telephone interview, with a knowledgeable
informant using the Dementia Questionnaire (DQ). Based on the interview, those subjects
who were rated as significantly cognitively impaired or with dementia or who were
members of a designated panel of participants to complete all stages of screening, were
sent for clinical assessment (CA). The CA consisted of a registered nurse (RN) interview
with a knowledgeable informant regarding the participant’s history of cognitive
symptoms, medical history, and current medications. The participant also received a
physical examination, which consisted of anthropomorphic measurements, blood pressure
and neurological exam, as well as neuropsychological assessment with a trained
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psychometrist (Breitner et al., 1999). The results of the CA were reviewed at an initial
diagnostic conference led by a study physician and a preliminary diagnosis of dementia
was rendered using the Diagnostic Statistical Manual-III-Revised (DSM-III-R) criteria
(American Psychiatric Association [APA], 1987). A diagnosis of AD was assigned if the
subject met criteria from the National Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) (McKhann et al., 1984) and that of vascular dementia if the subject
met criteria from the NINCDS-the Association Internationale pour la Recherche et
l’Enseignement en Neurosciences (AIREN; Román et al., 1993). Criteria for other
dementias followed standard research diagnostic criteria at the time (Breitner et al.,
1999). A follow-up CA (at approximately 18 months) was requested for those with a
diagnosis of a dementia or its prodrome. Neuroimaging and laboratory studies were
requested for those individuals with diagnoses of dementia or prodromal AD in order to
rule out other causes of cognitive impairment (Breitner et al., 1999). An independent
assessment was also conducted by a study physician. A final clinical diagnosis of
dementia was determined at a consensus conference with a panel of clinical experts
including a board-certified neurologist, geropsychiatrists, clinical neuropsychologists,
and a cognitive neuroscientist. Presence of dementia was determined based on the
participant’s performance on the CA, DSM-III-R criteria, physician CA, and laboratory
results and neuroimaging (Breitner et el., 1999). A classification of non-case was defined
as those who received a “non-case” diagnosis based on the CA, or lacking a CA, were
screen negative at prior stages of dementia screening. Age of onset for dementia was
assigned as the age at which the participant consistently met DSM-III-R criteria for
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dementia based on the chronological development of cognitive and functional
impairment. All study procedures were approved by the Institutional Review Boards at
Utah State University, Duke University, and the John Hopkins University. With the
completion of all four waves, 942 cases of dementia were identified, 546 (58%) with AD.
CCSMA data were supplemented with data from Medicare claims from 1992 to 2012,
and death certificates from 1909 to 2019, for an additional 209 cases of AD. See section
below on The Utah Population Database and Medicare Claims for detailed procedures.

CCSMA Derived Family History of Alzheimer’s Disease and Vascular Factors
Family history of AD was assessed through a structured interview and
administered at baseline and at subsequent waves. The interview ascertained information
about the participants’ biological parents and siblings and history of memory problems.
An endorsement of memory problems for each family member was followed up with
questions of the onset (sudden or gradual), course being progressive or static, and
whether the problems resulted in limitations in activities of daily living. A final question
asked if a physician diagnosed the cause of the memory issue. Each relative was
classified as having suspected AD if a physician had diagnosed AD, or lacking a
diagnosis, if the memory problems had worsened over time, and caused limitations with
daily activities. If a first-degree relative died before age 50 and did not have dementia,
that person’s information was coded as missing. A study participant was classified as
having a positive family history of AD if at least one first-degree relative was categorized
as having suspected AD (Hayden et al., 2009). Maternal and paternal family histories
were noted for each participant. Appendix A contains the family history questionnaire
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with the specific questions used to derive family history of AD. The UPDB linkage with
death certificates for extended genealogies supplemented family history information (see
Utah Population Database). Overall family history of AD and maternal and paternal
family histories were categorized using a combination of CCSMA self-report and
supplemented with data from the UPDB (see The Utah Population Database).
Cardiovascular risk factors were obtained in the context of a medical and
medication risk factor interview conducted at each wave of the CCSMA. History of
stroke was ascertained by the question, “Has a doctor or nurse ever told you that you had
a stroke?” Hypertension was ascertained through the question, “Have you been told by a
doctor that you had hypertension or have you been treated for hypertension?” High
cholesterol was asked with the question “Have you ever been told by a doctor you had
high blood cholesterol/triglycerides or have you ever been treated for high blood
cholesterol/trigylcerides?” Myocardial infarction was collected through the question
“Have you ever had a heart attack, a myocardial infarction, or a coronary thrombosis?”
Diabetes was ascertained through the question “Have you ever been told by a doctor you
had diabetes or have you been treated for diabetes?” Coronary Artery Bypass surgery was
ascertained through the question “Have you ever had a coronary bypass surgery?”
Appendix B presents the medical history questionnaire with the specific questions
associated with cardiovascular and related conditions. Additional risk factors and
conditions were asked in subsequent stages or waves, for example congestive heart
failure.
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The Utah Population Database
All but one of the participants of the CCSMA has been linked to the UPDB
(Norton et al., 2016). The UPDB is a computerized genealogy of founders of Utah and
their descendants (Cannon-Albright, 2008; https://uofuhealth.utah.edu/huntsman/utah
-population-database/). The database includes more than 11 million residents of Utah and
their relatives, of which 3 million individuals have at least 3 generations of genealogy
linked to the original Utah pioneers. Of the 3 million, 1.3 million have genealogy data
from at least 12 of 14 immediate ancestors including both parents, all four grandparents,
and at least six great-grandparents (Cannon-Albright et al., 2019). The genealogy data
have also been linked with the Utah Death Certificates from 1904 to 2019 and include the
primary cause of death using International Classification of Diseases (ICD)- 9th edition
and ICD-10 codes (Cannon-Albright et al., 2019). Additionally, the UBPD has been
linked to health care registries such as Utah Cancer Registry and Medicare Claims.
Further information about the UPBD can be accessed at https://uofuhealth.utah.edu
/huntsman/utah-population-database/data/.

Medicare Claims Database
Through the extensive linkage of the UPDB, there is access to Medicare claims
data that were submitted with ICD-9 conditions from the Centers for Medicare and
Medicaid services (CMS). Medicare offers health insurance for individuals aged 65 or
older to all citizens or permanent residents of the US. Data for this project used Medicare
claims that were available between 1992 to 2012. The ICD-9 billing codes were sought to
supplement the CCSMA cognitive status for AD dementia (ICD-9 code 331.0) as well as
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the following cardiovascular risk factors and conditions: hypertension (ICD-9 codes
401.1, 401.9), hyperlipidemia (272.39), diabetes mellitus (250, 205.12, 205.02), obesity
(278, 278.01), myocardial infarction (410.01-410.91; 412), stroke (433.01, 433.11,
433.21, 433.31, 433.81, 434.01, 434.11, 435.8, 435.9), atrial fibrillation (427.31) and
other arrythmias (427, 427.1, 427.2, 427.32, 427.41, 427.42, 427.69, 427.61, 472.81,
427.89), congestive heart failure (428), hypothyroidism (244.9), atherosclerosis (440.9,
440.8, 437, 440), and metabolic syndrome (277.7). In order to accept a claims diagnosis
for AD, criteria by Nair and colleagues (2018) were followed. Specifically, having at
least two claims of AD (331.0) at least 18 months apart (Nair et al., 2018). For vascular
risk factors and conditions, a single claim for an ICD-9 code was accepted as presence of
a condition. In order to be considered a risk factor, the cardiovascular condition had to
predate the age of diagnosis of AD.

Extended Maternal and Paternal Family History
Family history was expanded upon by using the UPDB’s linkage with the state’s
vital statistics database. For those with missing information on parental history regarding
cognitive status, cause of death codes related to AD and related dementias (ICD-9 code
331.0) were used. Individuals with AD as a primary or contributing factor of death were
coded as a positive family history of the disease. Second, third, and fourth generation
family histories of AD were also ascertained in the same manner.

Exceptional Parental Longevity
Parental longevity was determined using the CCSMA family history interview
and death certificate data as described above. The ages were classified for maternal and
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paternal longevity, with the following cut points: those individuals who survived to age
87 and older were classified as “exceptional longevity”.

Other Variables
Age at study entry (Wave 1), sex, and years of formal education were ascertained
through the CCSMA baseline interview. APOE genotype was available on 97% (4932) of
the participants (Breitner et al., 1999). These variables were used as covariates in
statistical models as described below.

Statistical Analyses
Inclusion criteria for the current analyses were outcomes of AD diagnosis or noncase (other forms of dementia and mild cognitive disorders such as MCI were excluded)
and family history information sufficient to determine family history of AD and maternal
and paternal longevity.
Descriptive statistics were used to characterize the sample with respect to
demographic attributes for those with a diagnosis of AD compared to non-cases. Group
differences were examined using Analysis of Variance (ANOVA) for continuous
variables and chi-square or Fisher’s exact tests for categorical variables.
Overall, to examine the association of each risk factor and the outcome of AD,
used binary logistic regression. Model building proceeded in which predictor variables
were examined systematically. First, variables were entered into the model to examine
main effects, followed by the inclusion of interaction terms. Those predictor variables
that were considered theoretically necessary or significant in the model at the p <.05 were
retained. For each of the models, covariates tested included: presence of an APOE Ɛ4
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allele, age at baseline, and education. To explore a non-linear association between age
and AD risk, a quadratic term for age (age2) was also examined in each model. The
models were compared using r-squared, ANOVA, Akaike’s Information Criteria (AIC),
and Bayesian Information Criteria (BIC) to determine the goodness of fit. The
performance package in R (Lüdecke et al., 2021) was used to compare each model’s
overall quality and goodness of fit through r-squared, root mean squared error, interclass
correlation, AIC, and BIC in one comparison table and provided a rank order list of the
models. The final model retained for each research question included the predictor
variables that met the criteria described above (statistical significance or theoretical
importance) and those models that provided the best goodness of fit while being most
parsimonious model given the above criteria. All statistical analyses were conducted in R
Studio R-Version 4.0.4 (RStudio Team, 2021).
To address research question one, binary logistic regressions (separate models for
sex) were used to examine extended family history of AD and risk for AD. Predictors
included AD classification for first-degree relative (parents, siblings, and offspring),
second degree relative, and third degree relative (each variable contained any ancestor
within that degree that had a diagnosis of AD) associated with risk of AD in the proband.
An interaction between APOE Ɛ4 status by family history of AD was also tested in the
models.
To address research question two, binary logistic regression models (separate
models for sex), using dichotomous direct maternal and paternal lineage of AD (see
Appendix C for an illustration of maternal and paternal lineages), were used to examine
their risk of AD in the proband. The following interactions in predicting AD outcome
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were tested in the models: 1) direct maternal lineage by direct paternal lineage of AD 2)
APOE Ɛ4 status by direct maternal lineage of AD; and 3) APOE Ɛ4 status by direct
paternal lineage of AD.
To address research question three, binomial logistic regression models (separate
models for sex), using separate dichotomous variables for maternal exceptional longevity
and paternal exceptional longevity (or not), were used to examine whether each was
associated with risk of developing AD. The following interactions in predicting AD
outcome were also examined: 1) maternal exceptional longevity by APOE Ɛ4 status; 2)
paternal exceptional longevity by APOE Ɛ4 status; and 3.) maternal exceptional longevity
by paternal exceptional longevity.
The last research question concerned whether cardiovascular risk factors and
conditions modified any associations between direct maternal/paternal lineage of AD and
AD risk in the proband, and whether there were sex differences in these relationships.
Vascular variables were classified as a risk factor if the age at first Medicare claim or age
at first reported diagnosis of the condition in CCSMA predated the age of onset of AD.
Metabolic syndrome was removed as a risk factor as individuals with a Medicare claim
diagnosis (n=59) did not meet this criterion. Given the large number of health conditions,
frequencies were examined, and a tetrachoric correlation matrix (Revelle, 2020;
providing an inferred Pearson’s r for binary variables) was used to determine if each
binary cardiovascular risk factor was highly correlated (Revelle, 2020). To reduce issues
with multicollinearity in the statistical models, those significantly correlated with one
another, a tetrachoric r of at least .60 (Frost, 2020), and determined to have a biological
link were collapsed into a single binary category. Thus, atrial fibrillation and other
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dysrhythmias were collapsed as was cholesterol/triglycerides and atherosclerosis. To
quantitatively examine the severity of multicollinearity among the cardiovascular
variables, variance importance factor analysis provided an index measure of how much
variance of the estimated regression coefficient was increased due to collinearity
(Akinwande et al., 2015; cutoff was less than 5). None of the cardiovascular risk factors
exceeded the cutoff of five in the variance importance factor analysis; thus, all were
retained. The final cardiovascular variables included: CVA, diabetes (DM) mellitus,
hypertension (HTN), congestive heart failure (CHF),
triglycerides/cholesterol/atherosclerosis (chol/athero), atrial fibrillation and other
dysrhythmias (afib/dysrhythmias), hypothyroidism, and myocardial infarction (MI). The
cardiovascular variables that remained highly correlated (r = 0.6) were tested in separate
models (e.g., afib/dysrthymias and hypothyroidism). Given the number of cardiovascular
risk factors remaining, statistical methods were employed to enhance prediction accuracy
and interpretation of the vascular variables through random forest and least absolute
shrinkage and selection operator (lasso regression). Random forest is a machine learning
technique that helps examine complex relationships between a set of predictor variables
and the outcome variable (Breiman, 2001). Random forest utilizes a decision tree, but
reduces the increased variance associated with having a single decision tree by using
multiple decision trees to produce a more accurate prediction related to the outcome
variable (Breiman, 2001). This is obtained by a process of bootstrapping samples of the
original dataset, which are then used to build decision trees that are averaged to provide a
prediction of the best fitting predictors for the outcome variable by providing a mean
decrease in the Gini (Breiman, 2001). Lasso regression is also a method to help with
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variable selection and regularization. It provides a value (Lambda) that produces the
lowest possible mean squared error and those variables that survive a penalty, are
retained to help with variable reduction (Tibshirani, 1996). Random Forest and Lasso
regression are statistical methods that provided a systematic way of removing variables
from the model (Breiman, 2001; Tibshirani, 1996). The lasso regression and random
forest analyses were conducted in tandem; the predictor variables were then compared.
The predictor variables that overlapped in both analyses were considered quantitatively
as the most predictive outcome variables. Thus, for the final research question, the
starting point was the final model in research question 2. This model (separate models for
sex) was used as the base model. Vascular factors that were deemed to be highly
predictive in the models were added. After the inclusion of each of the vascular factors
into the base model, the following interactions were examined: 1) each vascular risk
factor by direct maternal lineage of AD 2) each vascular risk factor by direct paternal
lineage of AD and 3.) each vascular risk factor/condition by age at baseline.
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CHAPTER IV
RESULTS
Demographics
There were 3677 individuals who met eligibility criteria. Excluded (from the
5092) were 1,071 individuals who were diagnosed with other forms of dementia or mild
cognitive disorder (e.g., MCI), 134 individuals who had missing family history data, 209
individuals with missing maternal and paternal longevity data, and one individual who
was not linked to the UPDB. The resulting sample consisted of 98.0% white individuals
and 58.7% females. Mean (SD) age at baseline was 75.75, SD= 7.11. There were 825
individuals diagnosed with AD, 686 of whom had received a diagnosis from CCSMA,
126 from their death certificate, and 83 from Medicare claims. Compared to males,
females were more likely to have AD (24.9% compared to 18.9% in males) and were
more likely to have a high school/GED or less than high school education (57.5%
compared to 44.7.% in males). Mean age of onset of AD for females was 82.62, SD= 6.57
and 81.61, SD= 6.96, for males. Table 1 presents the baseline characteristics for the
overall sample by sex.
Family History and Risk of Alzheimer’s Disease: Female Probands
Compared to non-case females, those who developed AD were more likely to
have an APOE Ɛ4 allele (57% compared to 26.2) and a first-degree relative with AD
(31.9% compared to 19.1%). Table 2 presents the risk factors by cognitive outcome.
Among females, having a first-degree relative with AD (vs. none) was associated
with a 66% increase in the odds of developing AD, Odds Ratio (OR) = 1.66, 95%
Confidence Interval (CI) [1.31-2.10], p = <.001, when controlling for age at baseline,
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Table 1
Overall Baseline Characteristics by Sex
Males
(n = 1520)
Characteristic

n

%

M

Females
(n = 2157)
SD

n

%

538
1619

24.9
75.1

M

SD

X2

t

Individual-Level Variables
Alzheimer’s Disease
Positive AD Diagnosis
Non-Case

18.47**
287
1233

18.9
81.1

Age at baseline
Education
High School or Less
Greater than High School
APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

74.98

6.84

76.30

7.25

-5.63**
57.59**

680
840

44.7
55.3

480
1040

31.6
68.4

1240
917

57.5
42.5
0.34

702
1455

32.5
67.5

Family History Variables
Direct Maternal Lineage of ADa
Positive History
Negative History

186
1334

12.2
87.8

248
1909

11.5
88.5

Direct Paternal Lineage of ADa
Positive History
Negative History

94
1426

6.2
93.8

113
2044

5.2
94.8

First-Degree Relative with ADb
At Least One
None

329
1191

21.6
78.4

487
1670

22.6
77.4

285
1235

18.8
81.2

414
1743

19.2
80.8

947
573
947

62.3
37.7
62.3

1286
871
1286

59.6
40.4
59.6

Second-Degree Relative with ADc
At Least One
None
Third-Degree Relative with ADd
At Least One
None
At Least One

0.4

1.33

0.4

0.09

2.58

Any Relative with AD Extending
Back 4 Generations
At Least One
None

0.56
1090
430

71.7
28.3

1521
636

70.5
29.5

Maternal Longevity
Survival to age 87
Survival to age 86 or below

489
1031

32.2
67.8

717
1440

33.2
66.8

Paternal Longevity
Survival to age 87
Survival to age 86 or below

300
1220

19.7
80.3

424
1733

19.7
80.3

0.42

0

Cardiovascular Variables
Atrial Fibrillation
Yes
None

50
1470

3.3
96.7

70
2087

3.2
96.8

0

Stroke
Yes
None

142
1378

9.3
90.7

216
1941

10
10

0.38
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Males
(n = 1520)
Characteristic

n

%

M

Females
(n = 2157)
SD

n

%

Diabetes Mellitus
Yes
None

316
1204

20.8
79.2

371
1786

17.2
82.8

Hypertension
Yes
None

768
752

50.5
49.5

1366
791

63.3
36.7

Cholesterol/Triglycerides
Yes
None

588
932

38.7
61.3

901
1256

41.8
58.2

Obesity
Yes
None

—e
1517

—e
99.8

12
2145

0.6
99.4

Hypothyroidism
Yes
None

41
1497

2.7
97.3

120
2037

5.6
94.9

Myocardial infarction
Yes
None

344
1176

22.6
77.4

258
1899

12
88

Atherosclerosis
Yes
None

33
1487

2.2
97.8

51
2106

2.4
97.6

Other Dysrhythmias
Yes
None

69
1451

4.5
95.5

90
2067

4.2
95.8

Congestive Heart Failure
Yes
None

85
1435

5.6
94.4

176
1981

8.2
91.8

M

SD

X2
7.33*

59.48**

3.4

2.01

16.81**

73.37**

0.78

0.21

8.53*

Note. N = 3677. AD = Alzheimer’s disease; APOE = apolipoprotein; GED = General Educational Development.
a Direct Lineage is parents, grandparents and great grandparents extending back three generations.
b Parents, siblings, offspring
c Grandparents, grandchildren, half-siblings, aunts/uncles, nieces/nephews
d First cousins, great grandparents, great grandchildren, great aunts/uncles
e Subsample size was suppressed because it was under the Health Portability and Accountability Act’s (HIPAA’s)
threshold for reporting data on this variable.
*p < .05. **p < .001.

t
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age2, education, and the presence of an APOE Ɛ4 allele. P-values for each predictor
ranged from p =<.001 to .380 (see Table 3). Figure 1 presents a probability plot of risk of
AD for females with compared to those without a first-degree relative with AD across
various ages. Probability plots were produced in R (RStudio Team, 2021), and represent
the division of the odds by one plus the odds. Binary logistic regression models for
having a second-degree relative only, third-degree relative only, or any relative with AD
were not significant. The interaction between the presence of an APOE Ɛ4 and each of
the above family history variables was also not significant (each interaction p > .126).

Table 2
Predictor Variables by Alzheimer’s disease or Non-Case Outcomes in Female Probands
Alzheimer’s Disease
(n = 551)

Non-Case
(n = 1643)
Characteristic

n

%

Age at baseline

M

SD

75.14

6.84

n

%

Education
High School or Less
Greater than High School

942
701

57.3
42.7

321
230

58.3
41.7

APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

430
1213

26.2
73.8

284
267

51.5
48.5

First-Degree Relative with ADa
At Least One
None

313
1330

19.1
80.9

176
375

31.9
68.1

Second-Degree Relative with ADb
At Least One
None

298
1345

18.1
81.9

118
433

21.4
78.6

Third-Degree Relative with ADc
At Least One
None

960
683

58.4
41.6

327
224

59.3
40.7

Any Relative with AD Extending
Back Four Generations
At Least One
None

M

SD

79.63

7.32

X2

0.11

119.83**

38.85**

0.11

3.92*
1123
520

68.4
31.6

402
149

Note. N = 2194. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a Parents, siblings, offspring
b Grandparents, grandchildren, half-siblings, aunts/uncles, nieces/nephews
c First cousins, great grandparents, great grandchildren, great aunts/uncles
*p < .05. **p < .001.

73
27

t
-13.1**
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Table 3
Females: Binary Logistic Regression With Extended Family History
Parameter

b

Intercept
Age, Years
Age2, Years
APOE Ɛ4 Status
Education, High School
Education or Less
First-Degree Relative with ADa

-0.21
0.40
-0.002
1.26
0.10
0.51

SE
5.46
0.14
0.0008
0.11
0.11
0.12

Wald

df

-3.83
2.87
-2.19
11.40
0.88

1
1
1
1
1

4.22

1

OR

OR 95% CI
Lower
Upper

<.001**
.004*
.029*
<.001**
.380

8.08-10
1.48
0.998
3.53
1.10

1.65-14
1.14
0.996
2.84
0.89

3.38-05
1.95
0.998
4.38
1.36

<.001**

1.66

1.31

2.10

Sig.

Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most
parsimonious. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a

Parents, siblings, offspring

*p < .05. **p < .001.

Figure 1
Female Probands: First Degree Relative With Alzheimer’s Disease

Note. This figure presents the probability of AD for females without the presence of an APOE Ɛ4 allele and
with a high school/GED or less education by a first-degree relative with AD (vs. none) across various ages.
First-degree relatives include parents, siblings, and offspring. AD= Alzheimer’s Disease.
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Family History and Risk of Alzheimer’s Disease: Male Probands
Males with AD compared to non-cases, were more likely to have an APOE Ɛ4
allele (51.6% vs. 26.8%), a first-degree relative with AD (30.4% compared to 19.2%), a
third degree relative with AD (66.8% vs. 60.2%), and at least one relative with AD
extending back four generations (76.8% compared to 69.4). Table 4 presents the predictor
variables for males by cognitive outcome.

Table 4
Predictor Variables by Alzheimer’s Disease or Non-Case Outcomes in Male Probands
Alzheimer’s Disease
(n = 289)

Non-Case
(n = 1252)
Characteristic

n

%

Age at baseline

M

SD

75.10

6.86

n

%

SD

X2

77.92 7.27

Education
High School or Less
Greater than High School

550
702

43.9
56.1

140
149

48.4
51.6

APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

336
916

26.8
73.2

149
140

51.6
48.4

First-Degree Relative with ADa
At Least One
None

241
1011

19.2
80.8

88
201

30.4
69.6

Second-Degree Relative with ADb
At Least One
None

224
1028

17.9
82.1

62
227

21.5
78.5

Third-Degree Relative with ADc
At Least One
None

754
498

60.2
39.8

193
96

66.8
33.2

Any Relative with AD Extending
Back Four Generations
At Least One
None

M

t

-7.9**
1.76

65.39*

16.88**

1.74

3.99*

5.88*
869
383

69.4
30.6

222
67

76.8
23.2

Note. N = 1541. AD = Alzheimer’s Disease; APOE = Apolipoprotein; GED = General Educational Development.
a Parents, siblings, offspring
b Grandparents, grandchildren, half-siblings, aunts/uncles, nieces/nephews
c First cousins, great grandparents, great grandchildren, great aunts/uncles
*p < .05. **p < .001.
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Among males, having a first-degree relative with AD (vs. none) was associated
with a 58% increase in the odds of developing AD, OR = 1.58, 95% CI [1.16-2.13], p =
.003, when controlling for baseline age, education, and the presence of an APOE Ɛ4
allele. P-values for each predictor ranged from p=<.001 to .414 (see Table 5). Figure 2
presents a probability plot of risk of AD for males with a first-degree with AD compared
to those without a first-degree relative with AD across various ages. Binary logistic
regression models for having a second-degree relative only, third-degree relative only, or
at least one relative with AD extending back four generations were not significant. The
interaction between presence of an APOE Ɛ4 allele and each of the above family history
variables was also not significant (each interaction p > .230)

Table 5
Males: Binary Logistic Regression With Extended Family History
OR 95% CI
Parameter

b

SE

Wald

df

Sig.

Intercept
Age, Years
APOE Ɛ4 Status
Education, High School
Education or Less
First-Degree Relative with ADa

-8.55
0.08
1.19
0.12

0.80
0.01
0.14
0.14

-10.64
8.53
8.40
0.82

1
1
1
1

<.001**
<.001**
<.001**
.414

0.45

0.16

2.93

1

.003*

OR

Lower

Upper

0.0001
1.09
3.30
1.12

0.00004
1.07
2.50
0.85

0.0009
1.11
4.36
1.48

1.58

1.16

2.13

Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most
parsimonious. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a

Parents, siblings, offspring

*p < .05. **p < .001.
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Figure 2
Male Probands: First Degree Relative With Alzheimer’s Disease

Note. This figure presents the probability of AD for males without the presence of an APOE Ɛ4 allele and
with a high school/GED or less education by a first-degree relative with AD (vs. none) across various ages.
First-degree relatives include parents, siblings, and offspring. AD = Alzheimer’s Disease.

Risk of Alzheimer’s Disease for Direct Maternal and Paternal Lineage of
Alzheimer’s Disease Among Female Probands
Female probands with AD were more likely to be older, have an APOE Ɛ4 allele
(51.7% compared to 26.1%) and a direct maternal lineage of AD (13.9% vs. 10.5%)
compared to non-case females. Table 6 presents the predictor variables for direct
maternal and paternal lineage of AD for female probands.
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Table 6
Predictor Variables Including Maternal and Paternal Lineage of Alzheimer’s Disease
and Cognitive Outcomes in Female Probands
Alzheimer’s Disease
(n = 567)

Non-Case
(n = 1707)
Characteristic

n

%

Age at baseline

M

SD

75.13

6.86

n

%

Education
High School or Less
Greater than High School

1304
920

57.3
42.7

330
237

58.2
41.8

APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

446
1261

26.1
73.9

293
274

51.7
48.3

Direct Maternal Lineage of ADa
Positive History
Negative History

179
1528

10.5
89.5

79
488

13.9
86.1

Direct Paternal Lineage of ADa
Positive History
Negative History

82
1625

4.8
95.2

39
528

6.9
93.1

M

SD

79.68

7.30

X2

t
-13.47**

0.18

125.48**

4.69*

3.24

Note. N = 2274. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a Direct Lineage is parents, grandparents and great grandparents extending back three generations.
*p < .05. **p < .001.

Compared to females with no family history of AD, direct maternal (but not
paternal, p = .101) lineage of AD was associated with a 56% increase in the odds of
developing AD, OR = 1.56, 95% CI [1.14-2.13], p = .005, when controlling for age at
baseline, age2, education, and presence of the APOE Ɛ4 allele. Figure 3 presents a
probability plot of risk of AD for females with a direct maternal lineage of AD across
various ages. P-values for each predictor variable ranged from p =<.001to .427 (see
Table 7). The interaction between the presence of an APOE Ɛ4 and the above direct
lineage variables was non-significant as was the interaction between direct maternal and
paternal lineage of AD (p values ranged from .133 to .757).
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Table 7
Females: Binary Logistic Regression With Direct Maternal and Paternal Lineage of
Alzheimer’s Disease
OR 95% CI
Parameter
Intercept
Direct Maternal Lineage of AD
Direct Paternal Lineage of AD
APOE Ɛ4 Status
Education, High School
Education or Less
Age, Years
Age2, Years

b

SE

Wald

df

-22.91
0.45
0.37
1.26
0.08

5.38
0.22
0.22
0.11
0.11

-5.05
2.43
1.79
10.77
1.17

1
1
1
1
1

0.14
0.0009

4.11
-3.52

1
1

0.44
-0.002

Sig.

OR

<.001** <0.001
.005*
1.56
.101
1.44
<.001**
3.53
.427
1.09
.001*
.012*

1.55
0.998

Lower

Upper

0.000
1.14
0.92
2.86
0.88

0.000
2.13
2.22
4.39
1.34

1.19
0.996

2.03
0.999

Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious.
AD = Alzheimer’s Disease; APOE = Apolipoprotein.
*p < .05. **p < .001.

Figure 3
Direct Maternal Lineage of Alzheimer’s Disease in Females

Note. This figure presents the probability of AD for females without the presence of an APOE Ɛ4 allele and
with a high school/GED or less education by a direct maternal lineage of AD (vs. none) across various
ages. Direct Maternal Lineage of AD is presented in Appendix C. AD = Alzheimer’s Disease.
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Risk of Alzheimer’s Disease for Direct Maternal and Paternal Lineage of
Alzheimer’s Disease Among Male Probands
Compared to male non-cases, males with AD were more likely to be older at
baseline and have an APOE Ɛ4 Allele. Predictor variables for maternal and paternal direct
lineage of AD for male probands is presented in Table 8.

Table 8
Predictor Variables Including Maternal and Paternal Lineage of Alzheimer’s Disease
and Cognitive Outcomes in Male Probands

Characteristic

n

Non-Case
(n = 1314)
%
M

Age at baseline

75.10

SD

Alzheimer’s Disease
(n = 299)
n
%
M
SD

6.85

X2

77.94 7.31

Education
High School or Less
Greater than High School

796
995

44.4
55.6

143
156

47.8
52.2

APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

348
966

26.5
73.5

155
144

51.8
48.2

Direct Maternal Lineage of ADa
Positive History
Negative History

157
1157

11.9
88.1

42
257

14
86

Direct Paternal Lineage of ADa
Positive History
Negative History

76
1238

5.8
94.2

21
278

7
93

t

-7.94**
1.47
71.79**

0.81

0.46

Note. N = 1613. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a Direct Lineage is parents, grandparents and great grandparents extending back three generations.
*p < .05. **p < .001.

Among males, neither maternal, OR= 1.38, p= .19, nor paternal, OR= 1.69, p=
.07, lineage of AD was associated with risk of AD in the proband. However, an
interaction between maternal and paternal lineage was significant at a trend level p = .054
level, OR= 0.22, 95% CI [0.05-0.93], with males who had both a direct maternal and
paternal lineage of AD having a 51.3% reduced odds of developing AD compared to
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males with neither. This result was maintained with the following covariates: age at
baseline, presence of an APOE Ɛ4 allele, and education. P-values for the covariates
ranged from p= < .001 to .433 (see Table 9). Figure 4 presents a probability plot of the
risk of AD for males from the model with the interaction between paternal and maternal
lineage of AD. The interactions between the presence of an APOE Ɛ4 allele and each of
the family history variables were not significant (each interaction p> .117).

Table 9
Males: Binary Logistic Regression With Direct Maternal and Paternal Lineage of
Alzheimer’s Disease
OR 95% CI
Parameter
Intercept
Direct Maternal Lineage of AD
Direct Paternal Lineage of AD
APOE Ɛ4 Status
Education, High School
Education or Less
Age, Years
Direct Maternal Lineage of AD
× Direct Paternal Lineage of
AD

b

SE

Wald

df

-8.76
0.27
0.52
1.23
0.11

0.80
0.21
0.21
0.30
0.14

-10.96
1.30
1.78
8.90
0.78

1
1
1
1
1

0.09
-1.41

0.14
0.73

8.94
-1.92

1
1

Sig.

OR

Lower

Upper

<.001**
.193
.074
<.001**
.433

0.0001
1.31
1.69
3.48
1.11

0.000
0.86
0.93
2.65
0.85

0.000
1.96
2.98
4.59
1.47

<.001**
.054

1.09
0.22

1.07
0.05

1.11
0.93

Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious.
AD = Alzheimer’s Disease; APOE = Apolipoprotein.
*p < .05. **p < .001.
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Figure 4
Direct Parental Lineage of Alzheimer’s Disease in Males

Note. This figure presents the probability of AD for males without the presence of an APOE Ɛ4 allele and
with a high school/GED or less education by a direct maternal and/or paternal lineage of AD (vs. none)
across various ages. This model is not the most parsimonious, however, and includes a trend level
interaction between maternal and paternal lineage of AD in male probands. AD = Alzheimer’s Disease.

Parental Exceptional Longevity and Alzheimer’s Disease Among Female Probands
Females with AD compared to female non-cases, were more likely be older
(79.72 compared to 75.16) and have a first-degree relative with AD (32.5% vs. 19.3%),
but did not differ by parental longevity. Table 10 presents the predictor variables for
females with parental longevity for risk of AD.
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Table 10
Predictor Variables for Parental Longevity and Cognitive Outcomes in Female Probands
Alzheimer’s Disease
(n = 538)

Non-Case
(n = 1619)
Characteristic

n

%

Age at baseline

M

SD

75.16

6.85

n

%

1240
917

57.5
42.5

313
225

58.2
41.8

APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

702
1455

32.5
67.5

276
262

51.3
48.7

Maternal Longevity
Survival to age 87
Survival to age 86 or
below

717
1440

33.2
66.8

170
368

31.6
68.4

Paternal Longevity
Survival to age 87
Survival to age 86 or
below

317
1302

19.6
80.4

107
431

19.9
80.1

Parental Longevity
Survival to age 87
Survival to age 86 or
below

SD

X2

79.72 7.36

Education
High School or Less
Greater than High School

First-Degree Relative with
AD (Parents, Siblings,
Offspring)
At Least One
None

M

t

-12.64**
0.1

113.72

0.78

0.01

39.84**

312
1307

19.3
80.7

175
363

32.5
67.5

739
880

54.4
45.6

242
296

45
55

0.05

Note. N = 2157. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
*p < .05. **p < .001.

Neither exceptional maternal longevity, OR= 0.96, 95% CI [0.76-1.20], p= .713,
nor exceptional paternal longevity, OR=1.09, 95% CI [0.83-1.42], p=.537, was associated
with risk for AD in the proband, when controlling for age at baseline, education, and
first-degree relative with AD. P-values for the predictor variables ranged from <.001 to
.713 (see Table 11). The interaction between the presence of an APOE Ɛ4 allele and
exceptional maternal longevity and the interaction between each parental longevity
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variable were also not significant (each individual p > .597). However, the interaction
between paternal exceptional longevity and APOE Ɛ4 was significant at trend level, with
the presence of one or more APOE Ɛ4 alleles and having a longer-lived father being
associated with 4.59 greater odds of developing AD, OR= 4.59, p=.063.

Table 11
Females: Binomial Logistic Regression With Maternal and Paternal Longevity and Risk
of Alzheimer’s Disease
OR 95% CI
Parameter

b

SE

Wald

df

Sig.

OR

Intercept
Maternal Longevity
Paternal Longevity
First-Degree Relative with ADa
APOE Ɛ4 Status
Education, High School
Education or Less
Age

-9.14
-0.04
0.08
0.53
1.24
0.09

0.62
0.12
0.14
0.12
0.12
0.11

-14.80
-0.36
0.62
4.40
11.13
0.79

1
1
1
1
1
1

<.001** <0.000
.713
0.96
.537
1.09
<.001**
1.70
<.001**
3.47
.429
1.09

0.10

0.01

12.58

1

<.001**

1.10

Lower

Upper

<0.001
0.76
0.83
1.34
2.79
0.88

<0.001
1.20
1.42
2.15
4.32
1.35

1.08

1.11

Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious.
AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a

Parents, siblings, offspring

*p < .05. **p < .001.

Parental Exceptional Longevity and Alzheimer’s Disease Among Male Probands
Males with AD (vs. non-case), were older, more likely to have an APOE Ɛ4 allele
(59.1% compared to 31.6%) and have a first-degree relative with AD (30.7% compared
to 19.5%). Table 12 presents the predictor variables for male probands with parental
longevity and risk for AD.
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Table 12
Predictor Variables for Parental Longevity and Cognitive Outcomes in Male Probands
Alzheimer’s Disease
(n = 287)

Non-Case
(n = 1233)
Characteristic

n

%

Age at baseline

M

SD

74.29

6.55

n

%

541
692

43.9
56.1

139
148

48.4
51.6

APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

480
1040

31.6
68.4

149
138

51.9
48.1

Maternal Longevity
Survival to age 87
Survival to age 86 or
below

405
828

32.8
67.2

84
203

29.3
70.7

Paternal Longevity
Survival to age 87
Survival to age 86 or
below

243
990

19.7
80.3

57
230

19.9
80.1

Parental Longevity
Survival to age 87
Non-Longer-Lived
Parents

SD

X2

77.91 7.28

Education
High School or Less
Greater than High School

First-Degree Relative with
AD (Parents, Siblings,
Offspring)
At Least One
None

M

t

-7.73**
1.77

66.57**

1.21

0.00

16.31**

241
992

19.5
80.5

88
199

30.7
69.3

562
671

45.6
54.

129
158

44.9
55.1

0.02

Note. N = 1975. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a Parents, siblings, offspring
*p < .05. **p < .001.

In male probands, there was a significant interaction between APOE Ɛ4 and
exceptional maternal longevity (p = .020) and a significant interaction between maternal
and paternal exceptional longevity (p = .041). With respect to the results of APOE Ɛ4 and
maternal longevity, males who had a long-lived mother and at least one APOE Ɛ4 allele
had triple the odds of AD, OR=3.15, p = .020, compared to males with neither attribute.
Figure 5 presents the probability plot for males by exceptional maternal longevity and
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APOE Ɛ4 allele status across various ages. These results were obtained controlling for
age at baseline, education, any relative with AD, and paternal longevity. P-values for the
predictor variables ranged from p= <.001 to .401 (see Table 13).

Table 13
Males: Binomial Logistic Regression With Maternal and Paternal Longevity and Risk of
Alzheimer’s Disease
OR 95% CI
Parameter

b

SE

Wald

df

Intercept
Maternal Longevity
Paternal Longevity
First-Degree Relative with ADa
APOE Ɛ4 Status
Education, High School
Education or Less
Age, Years
Maternal Longevity × APOEƐ4
Status
Maternal Longevity × Paternal
Longevity

-8.66
0.43
0.28
0.46
1.43
0.12

0.83
0.21
0.20
0.16
0.17
0.14

-10.46
2.03
1.38
2.92
8.28
0.84

1
1
1
1
1
1

0.08
-0.71

0.01
0.31

8.34
-2.33

-0.82

0.40

-2.04

Sig.

OR

Lower

Upper

<.001** <0.001
.042*
1.54
.171
1.32
.004*
1.58
<.001**
4.17
.401
1.12

0.000
1.01
0.88
1.16
2.98
0.85

0.003
2.33
1.97
2.14
5.87
1.49

1
1

<.001**
.020*

1.09
0.49

1.07
0.27

1.11
0.89

1

.041*

0.44

0.19

0.95

Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious.
AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a

Parents, siblings, offspring

*p < .05. **p < .001.

With respect to the interaction between maternal and paternal longevity and risk
for AD, males with both a maternal and paternal history of exceptional longevity had an
11% lower odds of developing AD, OR= 0.89, p=.041. These results were obtained in a
model controlling for baseline age, any relative with AD, education, and presence of an
APOE Ɛ4 allele (p values ranged from <.001 to .401 for the covariates). See Table 13 for
the fully adjusted model and parameter estimates. Figure 6 presents a probability plot of
risk for AD for males by maternal and paternal longevity. The interaction between
paternal longevity and APOE Ɛ4 allele status was non-significant (p = .284).
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Figure 5
Maternal Longevity and APOE Status in Male Probands and Risk for Alzheimer’s
Disease

Note. This figure presents the probability of AD for males with a first-degree relative without AD and
without paternal longevity and with a high school/GED or less education by maternal longevity and APOE
Ɛ4 allele status across various ages. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
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Figure 6
Maternal and Paternal Longevity in Male Probands and Risk for Alzheimer’s Disease

Note. This figure presents the probability of AD for males with a first-degree relative without AD, paternal
longevity, and the presence of an APOE Ɛ4 allele and with a high school/GED or less education by
maternal longevity and paternal longevity across various ages. AD = Alzheimer’s Disease.

Cardiovascular Risk Factors With Family History and Alzheimer’s Disease
Tetrachoric correlation matrices were conducted to examine the associations
between variables. Those variables that correlated above the r= 0.60 were collapsed with
others based on the above criterion and their biological relationship (e.g., similar
condition). Thus, atrial fibrillation and other dysrhythmias were collapsed, as was
cholesterol/triglycerides and atherosclerosis. Afib/dysrhythmias remained highly
correlated with hypothyroidism and CHF, but as they were less related biologically, were
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tested separately in the model. Appendix D presents the output of the tetrachoric
correlation matrices. Random forest analyses were conducted separately for each
variable. In females, hypothyroidism, afib/dysrhythmias, CHF, HTN, and chol/athero
resulted in the greatest decrease in the mean Gini (Gini importance is a metric of
decreasing misclassification of the outcome variable, with smaller values indicating
better classification accuracy; Menze et al., 2009; see Appendix D). In males,
afib/dysrhythmias, hypothyroidism, CHF, MI, and HTN reduced the mean Gini (see
Appendix D). Using the LASSO regression procedure with a cross-validated Lambda
(Lambda value corresponding to the minimum mean-squared error; Tibshirani, 1996)
found CHF, CVA, DM, obesity, hypothyroidism, and afib/dysrhythmias most predictive
of the outcome variable for both females and males (see Appendix D). The random forest
and Lasso regression outcomes were used in tandem to select the above-mentioned
vascular variables for the binary logistic regression models for each sex.

Examination of Cardiovascular Risk Factors With Family History and Alzheimer’s
Disease Among Female Probands
Among females, those with AD (vs. non-case) were more likely to have a history
of a CVA (15.7% vs. and 8%), obesity (2.6% compared to 0%), hypothyroidism (22.2%
vs. 0%), afib/dysrhythmias (22.4% compared to 0%), CHF (15.7% vs. 2.8%), but less
likely to have chol/athero (37.6% compared to 44.1%). Table 14 presents the predictor
variables for the cardiovascular risk factors and family history of AD for female
probands.
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Table 14
Predictor Variables for Cardiovascular Risk Factors and Family History of Alzheimer’s
Disease and Cognitive Outcomes in Female Probands
Alzheimer’s Disease
(n = 567)

Non-Case
(n = 1707)
Characteristic

n

%

Age at baseline

M

SD

76.19

7.33

n

%

SD

X2

79.68 7.30

Education
High School or Less
Greater than High School

974
733

57.3
42.9

330
237

58.2
41.8

APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

446
1261

26.1
73.9

293
274

51.7
48.3

Direct Maternal Lineage of
ADa
Positive Maternal History
Negative Maternal
History

M

0.18

125.48**

4.69*
179
1528

10.5
89.5

79
488

13.9
79

Direct Paternal Lineage of
ADa
Positive Paternal History
Negative Paternal History

82
1625

4.8
95.2

39
528

6.9
93.1

Stroke
Yes
None

136
1571

8
92

89
478

15.7
84.3

Diabetes Mellitus
Yes
None

307
1400

18
82

85
482

15
85

Hypertension
Yes
None

1055
652

61.8
38.2

371
196

65.4
34.6

3.24

27.66**

2.47

2.24

Cholesterol/Triglycerides/
Atherosclerosis
Yes
None

752
955

44.1
55.9

213
254

37.6
62.4

Obesity
Yes
None

0
1707

0
100

15
552

2.6
97.4

Hypothyroidism
Yes
None

0
1707

0
100

126
441

22.2
77.8

Myocardial infarction
Yes
None

211
1496

12.4
87.6

68
499

12
88

t

-13.47**

7.07*

41.51**

397.35**

0.02
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Alzheimer’s Disease
(n = 567)

Non-Case
(n = 1707)
Characteristic

n

%

M

SD

n

%

Atrial Fibrillation and Other
Dysrhythmias
Yes
None

0
1707

0
100

127
440

22.4
77.6

Congestive Heart Failure
Yes
None

47
1660

2.8
97.2

137
430

15.7
75.8

M

SD

X2

400.72*

259.45**

Note. N = 2274. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a Parents, siblings, offspring
*p < .05. **p < .001.

t
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Among females, there was an interaction between CHF and paternal lineage of
AD such that those with both attributes were at a 2-fold increase in the odds of
developing AD, OR= 2.26, p =.013, compared to those females with neither attribute. See
Figure 7 for a probability plot for females with a history of CHF and a direct paternal
linage of AD.

Figure 7
Females With Direct Paternal Lineage of Alzheimer’s Disease and Congestive Heart
Failure With Risk for Alzheimer’s Disease

Note. This figure presents the probability of AD for female probands without the presence of an APOE Ɛ4
allele, MI, CVA, direct maternal lineage of AD, and with a high school/GED or less education by a history
of CHF and direct paternal lineage of AD across various ages. AD = Alzheimer’s Disease; CHF =
Congestive Heart Failure; Pat = Paternal.
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Among the other vascular variables examined, females with a history of MI had a
40% lower-odds of developing AD, OR=0.60, 95% CI [.42-0.84], p= .004, than those
without a history of MI (see Figure 8), while those with a history of a CVA were at a
two-fold greater risk of developing AD, OR= 2.11, 95% CI [1.50-2.96], p= <.001 (see
Figure 9). The above results were obtained in models controlling for age at baseline,
presence of an APOE Ɛ4 allele, and education. P-values for the predictor variables ranged
from p=<.001 to .564 (see Table 15). Note that a trend level-interaction existed between
paternal lineage of AD and chol/athero such that those who had both attributes had a 2.69
greater odds of developing AD, OR= 2.69, p=.076. The interactions between the
additional cardiovascular risk factors risk factors and family history variables were nonsignificant (each individual p >.192; refer to Appendix E; Table E.1).

Table 15
Female: Binary Logistic Regression With Cardiovascular Risk Factors and Family
History of Alzheimer’s Disease
OR 95% CI
Parameter

b

SE

Wald

df

Sig.

OR

Intercept
Congestive Heart Failure
Myocardial Infarction
Cerebrovascular Accident
Direct Maternal Lineage of AD
Direct Paternal Lineage of AD
APOE Ɛ4 Status
Education, High School
Education or Less
Age, Years
Direct Paternal Lineage of AD ×
Congestive Heart Failure

-9.27
2.44
-0.51
0.74
0.45
0.53
1.34
0.07

0.64
0.20
0.18
0.17
0.17
0.23
0.12
0.11

-14.4
11.97
-2.87
4.31
2.69
2.26
11.63
0.58

1
1
1
1
1
1
1
1

<.001** <0.001
<.001** 11.15
.004*
0.60
<.001**
2.11
.007*
1.57
.024*
1.69
<.001**
3.85
.564
1.07

0.09
-2.10

0.01
0.83

11.89
-2.50

1
1

<.001**
.013*

1.10
0.12

Lower

Upper

<0.001
7.76
0.42
1.50
1.12
1.06
3.07
0.85

<0.001
11.72
0.84
2.96
2.17
2.67
4.84
1.33

1.08
0.02

1.12
0.71

Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious.
AD = Alzheimer’s Disease; APOE = Apolipoprotein.
*p < .05. **p < .001.
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Figure 8
Myocardial Infarction in Females and Risk for Alzheimer’s Disease

Note. This figure presents the probability of AD for females without the presence of an APOE Ɛ4 allele,
CHF, CVA, and direct lineage of maternal and paternal of AD and with a high school/GED or less
education by history of MI (vs. none). AD = Alzheimer’s Disease.
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Figure 9
Cerebrovascular Accident in Females and Risk for Alzheimer’s Disease

Note. This figure presents the probability of AD for female probands with a history of CVA (vs. none) by
risk for AD across various ages. This is for female probands without the presence of an APOE Ɛ4 allele,
MI, CHF, and direct maternal and paternal lineage of AD with a high school education/GED/ or less. AD =
Alzheimer’s Disease.

Cardiovascular Risk Factors With Family History and Alzheimer’s Disease Among
Male Probands
Compared to males without AD, those with AD were more likely to have a
history of HTN (57.9% compared to 48.9%), obesity (1% compared to 0%),
hypothyroidism (14% compared to 0%), afib/dysthymias (31.4% compared to 0%), and
CHF (20.7% compared to 0%). Table 16 presents the predictor variables for males with
cardiovascular risk factors and a family history of AD.
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Table 16
Predictor Variables for Cardiovascular Risk Factors and Family History of Alzheimer’s
Disease and Cognitive Outcomes in Male Probands
Alzheimer’s Disease
(n = 299)

Non-Case
(n = 1314)
Characteristic

n

%

Age at baseline

M

SD

74.29

6.55

n

%

575
739

43.8
56.2

143
156

47.8
52.2

APOE Ɛ4 Status
APOE Ɛ4 Present
APOE Ɛ4 Absent

348
966

26.5
73.5

155
144

51.8
48.2
0.81

157
1157

11.9
88.1

42
257

14
86

5.8
94.2

21
278

7
93

Stroke
Yes
None

104
1210

7.9
92.1

47
252

15.7
84.3

Diabetes Mellitus
Yes
None

262
1052

19.9
80.1

73
226

24.4
75.6

Hypertension
Yes
None

643
671

48.9
51.1

173
126

57.9
42.1

0.46

16.58**

2.7

7.41*

5.71*
501
813

38.1
61.9

137
162

45.8
54.2

1
99

Obesity
Yes
None

—b

—b

1314

100

3
296

Hypothyroidism
Yes
None

0
1314

0
100

42
257

14
86

Myocardial infarction
Yes
None

298
1016

22.7
77.3

69
230

23.1
76.9

t

-7.94**

71.79**

76
1238

Atrial Fibrillation and Other

X2

1.47

Direct Paternal Lineage of
ADa
Positive Paternal History
Negative Paternal History

Cholesterol/ Triglycerides/
Atherosclerosis
Yes
None

SD

77.94 7.31

Education
High School or Less
Greater than High School

Direct Maternal Lineage of
ADa
Positive Maternal History
Negative Maternal
History

M

8.36*

184.01**

0.01

432.95**
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Alzheimer’s Disease
(n = 299)

Non-Case
(n = 1314)
Characteristic

Dysrhythmias
Yes
None
Congestive Heart Failure
Yes
None

n

%

0
1314

26
1288

M

SD

n

%

0
100

94
205

31.4
68.6

2
98

62
237

20.7
79.3

M

X2

SD

162.53**

Note. N = 1613. AD = Alzheimer’s Disease; APOE = Apolipoprotein.
a Direct Lineage is parents, grandparents and great grandparents extending back three generations
*p < .05. **p < .001.

t
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Unlike females, there were no interactions between vascular variables and
parental family history. Individual vascular factors were associated with increased risk
for AD. Specifically, males with CHF had 11 times greater odds of developing AD,
OR=11.10, 95% CI [7.31-20.42], p=<.001, those with a history of a CVA were 74% more
likely to develop AD, OR= 1.74, 95% CI [1.11-2.61], p=.013, those with a history of
HTN (vs. none) 37% more likely to develop AD, OR= 1.37, 95% CI [1.02-1.84], p=.035,
and those with a history of high chol/athero were at 48% more likely to develop AD,
OR= 1.48, 95% CI [1.10-2.01], p=.011, compared to those lacking the risk factor. These
results were obtained when controlling maternal family history, paternal family history,
presence of an APOE Ɛ4 allele, age at baseline, and education. P values for the predictor
variables ranged from p= <.001 to .660 (see Table 17). Figures 10-13 present the
probability plots for each of the main effects above for male probands across various
ages. While only main effects were significant for each of the vascular variables, there
was a trend level interaction between CVA and direct maternal lineage of AD (p
interaction = 0.069). Specifically, having a history of CVA and maternal lineage of AD
was associated with a 34% reduced odds of AD, OR= 0.66 (see Appendix F for Table F.1
and Figure F.1). Appendix E; Table E.2 presents the other non-significant interactions
between vascular variables and parental lineage of AD.
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Table 17
Male: Binary Logistic Regression With Cardiovascular Risk Factors and Family History
of Alzheimer’s Disease
OR 95% CI
Parameter
Intercept
Congestive Heart Failure
Cerebrovascular Accident
Hypertension
Cholesterol/Triglycerides/
Atherosclerosis
APOE Ɛ4 Status
Direct Maternal Lineage of AD
Direct Paternal Lineage of AD
Education, High School
Education or Less
Age, Years

b

SE

Wald

df

Sig.

OR

Lower

Upper

-9.64
2.38
0.54
0.32
0.39

0.90
0.26
0.22
0.15
0.15

-10.68
9.08
2.48
2.10
2.55

1
1
1
1
1

<.001** <0.001
<.001** 11.10
.013*
1.74
.035*
1.37
.011*
1.48

<0.001
6.51
1.11
1.02
1.10

<0.001
11.83
2.61
1.84
2.01

1.28
0.15
0.29
0.06

0.15
0.21
0.28
0.15

8.59
0.69
1.03
0.44

1
1
1
1

<.001**
.492
.303
.660

3.61
1.15
1.33
1.07

2.70
0.76
0.75
0.80

4.84
1.74
2.27
1.43

0.09

0.01

8.47

1

<.001**

1.10

1.08

1.12

Note. The final model retained had the best fit (AIC, BIC, and R-squared) while also being the most parsimonious.
AD = Alzheimer’s Disease; APOE = Apolipoprotein.
*p < .05. **p < .001.
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Figure 10
Congestive Heart Failure in Males and Risk for Alzheimer’s Disease

Note. This figure presents the probability of AD for males without the presence of an APOEƐ4 allele, CVA,
HTN, chol/athero, and direct lineage of maternal and paternal of AD and with a high school/GED or less
education by history of myocardial infarction (vs. none). AD = Alzheimer’s Disease; CHF = Congestive
Heart Failure.
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Figure 11
Males With a History of Cerebrovascular Accident and Risk for Alzheimer’s Disease

Note. This figure presents the probability of AD for males without the presence of an APOEƐ4 allele, CHF,
HTN, chol/athero, and direct lineage of maternal and paternal of AD and with a high school/GED or less
education by history of myocardial infarction (vs. none). AD= Alzheimer’s Disease.
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Figure 12
Hypertension in Males and Risk for Alzheimer’s Disease

Note. This figure presents the probability of AD for males without the presence of an APOEƐ4 allele, CVA,
CHF, chol/athero, and direct lineage of maternal and paternal of AD and with a high school/GED or less
education by history of myocardial infarction (vs. none). AD = Alzheimer’s Disease.

65
Figure 13
Males With a History of Cholesterol/Triglycerides/Atherosclerosis and Risk for
Alzheimer’s Disease

Note. This figure presents the probability of AD for males without the presence of an APOEƐ4 allele, CVA,
CHF, HTN, and direct lineage of maternal and paternal of AD and with a high school/GED or less
education by history of myocardial infarction (vs. none). AD= Alzheimer’s Disease; Chol/Tri/Athero =
Cholesterol/Triglycerides/Atherosclerosis.

Table 18 presents the overall findings for female and male probands in the current
study.
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Table 18
Overall Summary of the Findings for Females and Males
Female

Male

First Degree Relative with AD

⇧ 66% (p = <.001; OR=1.66)

⇧ 58% (p=.003; OR=1.58)

Direct Maternal Lineage of AD

⇧ 56% (p= .005; OR= 1.58)

Not Significant

Direct Paternal Lineage of AD

Not Significant

Not Significant

Both Parental Lineage of AD

Not Significant

⇩ 51.3% (p=.054; OR=0.487)

Maternal Longevity

Not Significant

⇧ 54% (p=.041; OR= 1.54)

Paternal Longevity

Not Significant

⇧ 32% (p=.041; OR= 1.32)

Parental Longevity

Not Significant

⇧ 11% (p =.041; OR= 0.89)

Maternal Longevity and APOE Allele

Not Significant

⇧ 3.15-fold (p=.020; OR= 3.15)

CHF and Direct Paternal Lineage of AD

⇧ 2.26-fold (p=.013; OR=2.26)

Not Significant

Congestive Heart Failure

⇧ 11.15-fold (p=<.001; OR=11.15)

⇧ 11.10-fold (p=<.001; OR=11.10)

Myocardial Infarction

⇩ 40% (p =.004; OR=0.60)

Not Significant

Hypertension

Not Significant

⇧ 37% (p= .035; OR= 1.37)

Cholesterol/Triglycerides/Atherosclerosis

Not Significant

⇧ 48% (p= .011; OR= 1.48)

Cerebrovascular Accident

⇧ 2.11-fold (p= <.001; OR= 2.11)

⇧ 74% (p= .013; OR= 1.74)

Note. This was at a trend-level of significance. AD = Alzheimer’s Disease. CHF = Congestive Heart
Failure.
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CHAPTER V
DISCUSSION
In this population-based sample of 3677 individuals, familial characteristics were
associated with risk of AD, though some associations varied by sex. In both females and
males, having a first-degree relative with AD was associated with a 66% (females) and
58% (males) increase in the odds of developing AD compared to individuals lacking a
family history of AD. The risk of AD across the older age span varied by sex in that AD
risk among females declined at extreme ages (e.g., age 106) whereas in males, the risk
continued to increase well into the 100’s. In females, a direct maternal lineage of AD was
associated with a 56% increase in the odds of developing AD. Males having both a direct
maternal and paternal lineage of AD were at a 51.3% reduced odds at a trend level
significance compared to those with neither parental lineages. Variations by sex were
also found in the association of exceptional maternal and paternal longevity in risk for
AD, with females having no significant association with either parental exceptional
longevity. However, at a trend-level, females with a longer-lived father who also had an
APOE Ɛ4 allele had a 4.59-fold increase in the odds of developing AD compared to those
females without. Males with an APOE Ɛ4 allele who also had a longer-lived mother had
3.15 times the odds of developing AD compared to males lacking each risk factor. In
contrast, males with a longer-lived mother and longer-lived father had a 11% reduced
odds of developing AD. Cardiovascular risk factors as main effects were found to be
associated with risk of developing AD for both male and females, though differed slightly
with regards to particular cardiovascular risk factors/conditions in the magnitude of
increased odds. However, with respect to family history interactions with vascular
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factors, females with a direct paternal lineage of AD and a history of congestive heart
failure were at a 2.26-fold increased risk in the odds compared to those females without
either risk factor. Vascular factors including, CVA and CHF were associated with higher
odds of developing AD in both females and males, whereas a history of HTN and
chol/athero were associated with increased risk of AD in males only.
Previous research has established an association between family history of allcause dementia and risk for AD. Van Duijn and colleagues (1991) found in a re-analysis
of 7 case control studies a 3.5-fold greater risk of developing AD when having a firstdegree relative with all cause dementia, with greater risk associated with having two firstdegree relatives with all cause dementia (7-fold). Fratiglioni and colleagues (1993) also
found having a first-degree relative with all-cause is associated with a 3.2-fold increased
risk for AD. Research has also found an association with having a first-degree relative
with AD and increased risk in the proband. Cannon-Albright and colleagues (2019) found
having one first-degree relative with AD doubled the risk of developing AD in the
proband. The risk further doubled when having two first-degree relatives with AD and
increased to 14 times greater when having four first-degree relatives. The current study is
consistent with prior work, though the effects were several magnitudes lower in strength.
Not examined in the current study were numbers of first-degree relatives affected.
Unlike prior work, however, the current study did not find an association between
second-and-third degree family history of AD and risk of AD in either males or females.
Cannon-Alright and colleagues (2019) used cause of death codes on death certificates for
270,818 individuals in the state of Utah to examine the association between the
occurrence of AD in extended relatives and risk for AD in the proband. They found that
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having a second-degree relative in addition to a first-degree relative with AD increased
the risk two-fold and having an affected third-degree relative increased the risk of
developing AD by 43%. Here, we found no associations of AD risk (either increased or
decreased) for those with second-or third-degree relatives. The discrepant results are
likely associated with differences in methodology, in that the current project relied
primarily on self-report family history, supplemented death certificate AD diagnosis and
Medicare claims diagnosis of AD in the proband, as well as variation in the samples (e.g.,
statewide vs. a single county).
Existing research has also found a link between maternal and paternal
transmission of AD and risk for AD in the proband. In the Cannon-Albright study (2019),
there was a link between maternal but not paternal family history of AD and increased
risk of AD (56%) in the proband. Differences have also been reported in prior work with
AD risk or AD related biomarkers for maternal and paternal family history of AD (Honea
et al., 2012; Mosconi et al., 2007; Mosconi et al., 2010). In a cross-sectional study using
the Alzheimer’s Disease Neuroimaging Initiative (ADNI) data, Honea and colleagues
found that regardless of the cognitive status of the individual, a maternal family history of
AD was associated with increased uptake of Pittsburgh B Compound (PiB; a radiotracer
marks the deposition of amyloid-beta (Aβ) in the brain, a common biomarker of AD) in
the parietal and sensorimotor cortices and the precuneus (Honea et al., 2012). Mosconi
and colleagues (2007) found in a cross-sectional study that having a maternal family
history of AD was associated with reduced cerebrospinal fluid (CSF) Aβ and increased
tau/Aβ ratios compared to those participants with a paternal family history or no family
history of AD. The authors also found maternal family history of AD was linked to
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reduced brain glucose metabolism in the medial-temporal lobe, parietotemporal lobe,
posterior cingulate, and frontal cortices compared to those participants without a family
history of the disorder (Mosconi et al., 2007). In a follow-up study, Mosconi and
colleagues (2010) found that those individuals with a maternal family history of AD who
were otherwise cognitively normal at baseline had progressive reductions in brain
glucose metabolism over a two-year period when compared to those with a negative
family history or a paternal family history of AD. In contrast to the above studies,
Ehrenkrantz and colleagues (1999) found no evidence of maternal transmission of AD
but did find evidence of paternal transmission. While the underlying mechanism
associated with maternal and paternal history of AD and risk remains unclear, hypotheses
have implicated the role of mitochondrial DNA (Mosconi et al., 2010). Mitochondrial
DNA is typically passed down through the maternal lineage, though reports have found
biparental transmission (Luo et al., 2018). Mitochondria are associated with cell
metabolism and are cellular organelles that provide energy for cellular processes
(Wallace, 2005). Certain mitochondrial genotypes may be associated with reductions in
brain glucose metabolism or dysfunctional glucose utilization and thus serve as risk
factors for AD (Castro et al., 2018). Indeed, brain glucose metabolism is reduced in AD
(Mosconi et al., 2010) and dysfunction of mitochondrial chaperones (supportive
structures that maintain homeostasis by shuttling, refolding, and coordinating the
proteolytic system, thereby reducing the number of misfolded proteins) also occurs in AD
(Castro et al., 2018). Alternatively, lifestyle factors (e.g., diet, exercise, etc.) could be a
shared mechanism of familial transmission of AD as familial traditions are often passed
down through the generations (Lourida et al., 2019). The current study supports a
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relationship between direct maternal lineage and increased risk of AD in female
probands. Notably, the current study found that in males, having both a paternal and
maternal lineage of AD was associated with reduced risk. A potential explanation may
include the effects of the competing risk of mortality with age for those with AD in both
maternal and paternal lineages. Further research is needed to examine mechanisms of AD
risk with parental lineages.
The current study found differential risk of AD across the extreme age spectrum
for males and females. Prior work in the Cache County cohort reported a reduction in risk
at extreme ages. Miech and colleagues (2002) reported that both incidence of dementia
and AD exponentially increased until about ages 85 to 90, with decline in males at about
age 93 and a decline at age 97 for females. This relationship was modified by the
presence of an APOE Ɛ4 allele (Miech et al., 2002). We extended this work by adding an
additional 9 years of surveillance for AD. Additionally, methodological differences are
notable, in that the current work examined associations of AD obtained throughout the
study, whereas the previous analyses relied only on newly diagnosed cases in the 2nd
wave of the study. The relationship between longer-lived individuals and a reduction in
AD risk may relate to compression of morbidity (lower risk of health conditions).
Consistent with this notion is the finding in the current study that the decline in AD risk
in late life was no longer evident when including cardiovascular risk factors in statistical
models.
Longevity has been related to several social/environmental (e.g., diet and
exercise) and genetic factors (Sebastiani et al., 2012). A prior study of 424 communitydwelling older adults found that individuals with at least one parent surviving past 95
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years of age had a 43% reduction in risk of developing AD compared to those with
parents living fewer years (Lipton et al., 2010). Andersen and colleagues (2012) found a
delayed onset of at least one age related disease (cardiovascular disease, obstructive
pulmonary disease, dementia, diabetes, and stroke) in those with exceptional longevity
(aged 87 and older) compared to controls. Centenarians were observed to have a reduced
risk for cancer (91%), hypertension (85%), and dementia (64%) (Andersen et al., 2012).
Delay of onset of additional conditions and further reductions in the hazards were seen in
supercentenarians (102-112), suggesting that increasing age was associated with greater
reductions in morbidity (Andersen et al., 2012). Westendorp and colleagues (2009)
examined risk of morbidity among familial nonagenarians (two siblings aged 90 and
above), and sporadic nonagenarians (one individual aged 90 and above) and found
reduced prevalence rates of MI, DM, HTN, and the use of cardiovascular medication.
While reductions in morbidity have been found in longer-lived individuals, the presence
of a genetic risk factor such as APOE may modify the associations between parental
longevity and AD risk. The relationship between parental and offspring longevity is
complex and likely reflects the influence of multiple factors including the environment,
social/cultural practices, and genetics. Human twin studies have found that genetics
explained 20-30% of the variance in those individuals who survived to age 85 and above
(Herskind et al., 1996). Prior work has also shown extreme clustering of exceptional
longevity within some rare families (Alpert et al., 1998; Perls et al., 2000). Sebastiani and
colleagues (2012) found that 281 single nucleotide polymorphisms (SNPs; including
those associated with APOE) discriminated between controls and cases of exceptional
longevity with the greatest contribution of the SNPs being in those with older age
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(median of 100). The authors note that exceptional longevity is unlikely to be associated
with a single or a few genetic components, but rather genetic clusters (Sebastini et al.,
2012). They also recognized that lifestyle and other environmental factors contribute to
increased survival rates. The findings in the current study only found a relationship
between maternal and paternal longevity and risk of AD in males. The Cache County
cohort had greater longevity than the general population at the time (Breitner et al.,
1999). Lack of variance or homogeneity in lifestyle and other genetic factors may have
diminished the associations between longevity and reduced morbidity that were found in
other samples. Further research is needed to elucidate this relationship.
Previous literature has reported on sex differences with regards to risk of AD and
APOE Ɛ4 status in that, males with one APOE Ɛ4 allele exhibit little-to-no risk of AD
compared to male non-carriers (Bretsky et al., 1999), and those with two APOE Ɛ4 alleles
exhibit a 5-fold increase in risk (Payami et al., 1996). Among females, studies have found
a four-fold increased risk of developing AD when carrying an APOE Ɛ4 allele regardless
of having one or two Ɛ4 alleles. A prior study found, in a sample of 5,000 deceased and
autopsied individuals between the ages 25-96, middle-aged females carrying the APOE
Ɛ4 allele had more brain regions affected by AD pathology than male carriers of the
APOE Ɛ4 allele (Corder et al., 2004). The current study found an interaction in males
with parental longevity. Male APOE Ɛ4 carriers with a longer-lived mother showed a
greater risk for AD. A trend was found in females with an APOE Ɛ4 allele and a longerlived father being at greater risk for AD. These results may represent increased risk
associated with greater longevity in the proband and an underlying genetic predisposition
for AD.
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Sex differences are also known to exist in cardiovascular conditions, some as a
result of differences in gene expression from sex chromosomes (Garcia et al., 2016).
Existing research has also found an association between cardiovascular risk factors and
risk for AD (Barnes & Yaffe, 2011; Lennon et al., 2019). Prevalence and incidence rates
of cardiovascular conditions differ between the sexes, with females being more likely to
develop DM, strokes, and HTN after age 65 and males developing those conditions
earlier in life (Mosca et al., 2011). Additionally, females have a greater mortality rate
following strokes and coronary heart disease as well as increased morbidity at later ages
(Bots et al., 2017). Research has also found variance in the clinical features of
cardiovascular disease compared to males, with females expressing differences in the
symptoms of cardiovascular diseases such as MI (Mosca et al., 2011). Additionally,
estrogen has been found to be cardioprotective. Females after menopause are at greater
risk for CVD, high low-density lipoprotein (LDL) cholesterol levels, hypertension,
diabetes, and obesity (Rodgers et al., 2019). This suggests that sex-differences in
cardiovascular risk factors may be influenced by changes in hormones. Additional
research is needed to examine the underlying mechanisms associated with estrogen’s role
in cardiovascular conditions and risk for AD in women.
The current study found sex differences in the magnitude of effect for
cardiovascular predictor variables and AD. Females had double the risk with having a
history of a CVA, whereas males had a 74% increase in risk. Males and females had an
11-fold greater risk of AD with a history of CHF however, females had a two-fold
increase in risk when having a paternal history of AD. Only males showed an increased
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risk for AD with a history of HTN (37%), and for high cholesterol or atherosclerosis
being at a 2.69 increased risk for AD at a trend level significance.
Prior work has examined the association between vascular risk factors and
conditions and AD in the Cache County cohort (Hayden et al., 2006). Hayden and
colleagues (2006) found that obesity doubled the risk for females in the hazards of
developing AD, but not in males. They also found other cardiovascular risk factors were
associated with risk for vascular dementia (VaD) and this association also differed by
sex. The current study extends previous work by adding additional years of AD
surveillance and supplementing data on cardiovascular risk factors from Medicare claims.
Cardiovascular risk factors such as HTN, hypercholesteremia, and DM have been
associated with risk for AD (e.g., Lennon et al., 2019), particularly with onsets in mid-life
(Barnes & Yaffe, 2011). Honig and colleagues (2003) found a history of stroke was
associated with a 60% increase in the hazards for AD. Cholesterol has also been found to
be associated with AD and the APOE Ɛ4 allele (Sjögren & Blennow, 2005). Lennon and
colleagues (2019) in a systematic review found that systolic hypertension was associated
with a 25% increased risk. Additionally, a meta-analysis by Barnes and Yaffe (2011)
found that conditions occurring in mid-life (i.e., hypertension, obesity, and DM)
contributed to a significant portion of cases of AD. CHF in the current study, was among
the greatest risk factor for AD. CHF has been associated with cognitive decline
independently of AD and the structures affected by CHF significantly overlap with those
found to be affected by AD (e.g., hippocampus, precuneus, orbitofrontal cortex, etc.;
Alosco & Hayes, 2015; Mueller et al., 2020). Thus, CHF may represent a vulnerability
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factor (e.g., hypoxia and reduced cerebral blood flow to the inferior mesial temporal lobe
structures) rather than a condition that drives AD pathology.
The current study did not examine the use of pharmacological interventions for
treatment of CHF and the other cardiovascular conditions. Treatments for CHF include
diuretics, antihypertensives, and beta-blockers (American Heart Association [AHA],
2015). One common medication for the treatment of CHF is angiotensin-converting
enzyme (ACE) inhibitors (AHA, 2015), which previous literature has found to be
associated with reduced risk for AD (Soto et al., 2013). Similarly, within the Cache
County sample previous research has found a 30% and 31% reduced risk associated with
thiazide and potassium-sparing diuretics, respectively (Chuang et al., 2014). Conversely,
the use of medications such as beta-blockers has been associated with an increased risk of
dementia in older adults (Fares, 2012). Zandi and colleauges (2005) examined the use of
statins, and risk within the Cache County population and found that statin use at baseline
was not significantly associated with risk for dementia or AD nor was it associated with
progression to AD. Previous research suggests that various medications used to treat CHF
and other cardiac conditions may have varying effects on the overall risk of AD related to
the cardiac condition. Future research is needed to examine how various types of
pharmacological interventions for the cardiac conditions may modify their associations
with AD. The current study was also limited in its ability to examine the underlying cause
of CHF as well as various classes of CHF, which are associated with differences in
functional abilities and outcomes (AHA, 2015). There may be a specific underlying
etiology or specific classes of CHF that elevate the risk for AD and further research is
warranted.
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In general, the risk for cardiovascular conditions increases with age and is
associated greater risk of mortality (Virani et al., 2020). Future research is needed to
examine the competing risk of mortality versus AD and its association with
cardiovascular risk factors/conditions. Cardiovascular conditions are also associated with
reduced longevity (Virani et al., 2020), and thus those with parental family history of
cardiovascular conditions may have greater cardiovascular load and shorter survival time.
The current findings with cardiovascular risk factors/conditions and reduced risk and the
limited associations with family history may be related to the competing risk of mortality
and the survival time of the proband.
Significant overlap also exists between vascular dementia (VaD) and AD, which
increases with advanced age (Strub, 2003). Both disorders are associated with the
presence of cardiovascular conditions (Strub, 2003), though condition differ in their
pathophysiological mechanisms. The current study was restricted in examining AD and
did not examine the association with VaD. The presence of both VaD and AD, may have
different associations with cardiovascular risk factors and conditions. Future research
should examine the relationship between cardiovascular risk factors/conditions and
family history with risk of VaD in the proband.
A trend-level association was found in the current study in males with a history of
CVA and a direct maternal lineage of AD being at 34% reduced risk for AD. This finding
was unexpected and warrants replication in other samples.
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Study Strengths and Limitations
The current study had a number of strengths. The base Cache County Study was a
large community-based sample with 90% enrollment of the base population. Thus,
generalizability to other community-dwelling individuals is likely greater than studies
relying on samples from other settings, such as clinical sites or medical centers. The
follow-up extending up to 12 years is an additional strength. Furthermore, the rich dataset
was supplemented up to an additional seven years through the addition of Medicare
Claims and death certificate data via linkage with the UPDB. This linkage provided
greater surveillance of both AD (additional 209 cases of AD) and cardiovascular risk
factors and condition beyond the end of data collection. Additionally, UPDB linkage was
critical in providing data on extensive familial genealogy extending back four
generations. Nonetheless, data from Medicare claims and death certificates are limited.
Death certificates have been known to underestimate the prevalence of AD, as the
certifying physician may be unaware of an AD condition (Frecker et al.,1995; Raiford et
al., 1994). Alternatively, certifying physicians may assume an AD diagnosis for a
different form of dementia. For example, disorders that mimic the clinical symptoms of
AD such as limbic-predominant age-related TDP-43 encephalopathy (LATE) (Robinson
et al., 2020) and argyrophilic grain disease (Tolnay & Clavaguera, 2004). Medicare
claims data, which are used for billing purposes, are not a direct substitute for clinical
diagnoses (American Medical Association [AMA], 2014). To reduce misclassification for
AD from claims data, the current study required the occurrence of a minimum of two
ICD-9 AD claims within 18 months. This criterion is highly correlated with autopsy
confirmed diagnoses of AD (Nair et al., 2018). For cardiovascular risk factors and
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conditions, the age of onset inferred from Medicare claims data may post-date the actual
onsets as individuals are eligible for Medicare at age 65 (AMA, 2014). Many of the
chronic health conditions such as hypertension and hypothyroidism occur frequently in
mid-life (Fryar et al., 2017), and thus some conditions were not considered risk factors if
the inferred age of onset postdated the onset of AD. Despite the limitations with
Medicare claims and death certificates they were used to augment Cache County Study
data and the majority of the AD designations and risk factors were obtained from the
Cache County Study directly, mitigating these concerns. While the Cache County cohort
may be broadly generalizable as community-dwelling individuals, participants were
primarily white, of Northern European descent, and relatively highly educated. Thus,
study results may not generalize to other populations with greater ethnic and cultural
diversity. Lastly, the rich Cache County Study dataset with linkage to genealogical, state,
and federal health data allowed for the examination of sex differences, family history of
AD, familial exceptional longevity, and vascular factors as risk factors for AD within a
single sample.

Implications and Future Directions
There are several implications from the current study. This study highlights the
importance of ascertaining first-degree relative information about AD for both males and
females. It may also be beneficial clinically when working with patients to provide sexspecific interventions/counseling related to modifiable cardiovascular risk factors.
Heightened surveillance and treatment for males at risk for CHF, CVA, HTN, and
chol/tri/athero are warranted as a primary prevention strategy. Similarly, females at risk
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for CHF and CVA would also benefit from surveillance and primary prevention to reduce
future risk of AD. This includes changes in diet, improving sleep, increasing physical
activity, managing menopausal changes, and use of pharmacological interventions such
as ACE inhibitors, which has been associated with reducing risk for AD (Ju et al., 2013;
Soto et al., 2013; Tang et al.,1996; Tschanz et al., 2013; Yaffe et al., 2014) and
improving cardiovascular health (Shay et al., 2015). This study also supports the notion
of managing cardiovascular health as an area of lowering risk for AD and suggests the
benefit of providing sex-specific intervention strategies. Additionally, monitoring both
males and females for specific cardiovascular conditions when a positive first-degree
family history of AD, may also be an effective prevention strategy.
There was limited association between direct maternal and paternal lineage of AD
and cardiovascular risk factors. Future research should continue to assess these risk
factors and modifying relationships with risk for AD. Not examined in this study was
family history of vascular risk factors or conditions. A family history of stroke and MI
has been found to be more predictive of risk for the condition in females compared to
males (Patel et al., 2007; Touzé & Rothwell, 2007). Specifically, females who had
experienced a stroke were 15% more likely to have a first-degree relative with a history
of a stroke than males who had a stroke, and females with a paternal family history of a
stroke were at a 25% increased risk for a stroke compared to males with a similar family
history (Touzé & Rothwell, 2007). A study by Patel and colleagues (2007), found an
association with family history of MI and greater risk in females compared to males.
These studies suggest sex differences may exist in family history of vascular factors.
Future research on sex differences in AD and vascular factors is warranted. Research
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examining family history of AD and vascular factors together may potentially identify
high risk individuals for both conditions and a group for whom strategies in primary
prevention may be particularly beneficial. Overall, this study highlights the importance of
future research in exploring and clarifying the nature of sex differences in risk factors for
AD.

82
REFERENCES
American Heart Association. (2015). What is heart failure? https://www.heart.org//media/files/health-topics/answers-by-heart/what-is-heart-failure.pdf
American Medical Association. (2014). Medicare claims data release. https://www.amaassn.org/practice-management/medicare-medicaid/medicare-claims-data-release
Alzheimer’s Association. (2021). Alzheimer’s disease facts and figures.
http://alz.org/facts/overview.asp
Akinwande, M., Dikko, H., & Samson, A. (2015) Variance inflation factor: As a
condition for the inclusion of suppressor variable(s) in regression analysis. Open
Journal of Statistics, 5, 754–767. https://doi.org/10.4236/ojs.2015.57075
Alpert, L., Desjardins, B., Vaupel, J. W., & Perls, T. T. (1999). Extreme longevity in a
family: A report of multiple centenarians within a single generation. In B. Jeune
& J. Vaupel (Eds.), Validation of exceptional longevity (pp. 225–234). Odense
University Press.
Alosco, M. L., & Hayes, S. M. (2015). Structural brain alterations in heart failure: A
review of the literature and implications for risk of Alzheimer’s disease. Heart
Failure Reviews, 20(5), 561–571. https://doi.org/10.1007/s10741-015-9488-5
Andersen, S. L., Sebastiani, P., Dworkis, D. A., Feldman, L., & Perls, T. T. (2012).
Health span approximates life span among many supercentenarians: Compression
of morbidity at the approximate limit of life span. Journals of Gerontology Series
A: Biomedical Sciences and Medical Sciences, 67(4), 395–
405. https://doi.org/10.1093/gerona/glr223
Bairey-Merz, C. N. B., Shaw, L. J., Reis, S. E., Bittner, V., Kelsey, S. F., Olson, M.,
Delia Johnson, B., Pepine C. J., Mankad, S., Sharaf, B. L., Rogers, W. J., Pohost,
G. M., Lerman, A., Quyyumi, A. A., Sopko, G., & WISE Investigators (2006).
Insights from the NHLBI-sponsored women’s Ischemia Syndrome Evaluation
(WISE) study: Part II: Gender differences in presentation, diagnosis, and outcome
with regard to gender-based pathophysiology of atherosclerosis and
macrovascular and microvascular coronary disease. Journal of the American
College of Cardiology, 47(3 Supplement), S21–S29.
https://doi.org/10.1016/j.jacc.2004.12.084
Barnes, D. E., & Yaffe, K. (2011). The projected effect of risk factor reduction on
Alzheimer's disease prevalence. The Lancet Neurology, 10(9), 819–
828. https://doi.org/10.1016/S1474-4422(11)70072-2

83
Beam, C. R., Kaneshiro, C., Jang, J. Y., Reynolds, C. A., Pedersen, N. L., & Gatz, M.
(2018). Differences between women and men in incidence rates of dementia and
Alzheimer’s disease. Journal of Alzheimer's Disease, 64(4), 1077–
1083. https://doi.org/10.3233/JAD180141
Breiman, L. (2001). Random forests. Machine Learning, 45(1), 5–32.
https://doi.org/10.1023/A:1010933404324
Breitner, J. C., Wyse, B. W., Anthony, J. C., Welsh-Bohmer, K. A., Steffens, D. C.,
Norton, M. C., Tschanz, J. T., Plassman, B. L., Meyer, M. R., & Khachaturian, A.
(1999). APOE-ε4 count predicts age when prevalence of AD increases, then
declines: The Cache County Study. Neurology, 53(2), 321–321.
https://doi.org/10.1212/WNL. 53.2.321
Bretsky, P. M., Buckwalter, J. G., Seeman, T. E., Miller, C. A., Poirier, J., Schellenberg,
G. D., Finch, C. E., & Henderson, V. W. (1999). Evidence for an interaction
between apolipoprotein E genotype, gender, and Alzheimer disease. Alzheimer
Disease and Associated Disorders, 13(4), 216–221.
https://doi.org/10.1097/00002093-199910000-00007
Bots, S. H., Peters, S. A., & Woodward, M. (2017). Sex differences in coronary heart
disease and stroke mortality: A global assessment of the effect of ageing between
1980 and 2010. British Medical Journal Global
Health, 2(2). https://doi.org/10.1136/bmjgh-2017 000298
Cannon-Albright, L. A. (2008). Utah family-based analysis: Past, present and
future. Human Heredity, 65(4), 209–220. https://doi.org/10.1159/000112368
Cannon-Albright, L. A., Foster, N. L., Schliep, K., Farnham, J. M., Teerlink, C. C.,
Kaddas, H., Tschanz, J., Corcoran, C., & Kauwe, J. S. (2019). Relative risk for
Alzheimer disease based on complete family history. Neurology, 92(15), e1745–
e1753. https://doi.org/10.1212/WNL.0000000000007231
Castro, J. P., Wardelmann, K., Grune, T., & Kleinridders, A. (2018). Mitochondrial
chaperones in the brain: Safeguarding brain health and metabolism? Frontiers in
Endocrinology, 9, 196. https://doi.org/10.3389/fendo.2018.00196.
Centers for Disease Control. (2017). Fast facts life expectancy.
https://www.cdc.gov/nchs/fastats/life-expectancy.htm
Corder, E. H., Ghebremedhin, E., Taylor, M. G., Thal, D. R., OHM, T. G., & Braak, H.
(2004). The biphasic relationship between regional brain senile plaque and
neurofibrillary tangle distributions: Modification by age, sex, and APOE
polymorphism. Annals of the New York Academy of Sciences, 1019(1), 24–
28. https://doi.org/10.1196/annals.1297.005

84
Chuang, Y. F., Breitner, J. C., Chiu, Y. L., Khachaturian, A., Hayden, K., Corcoran, C.,
Tschanzg, J., Nortong, M., Mungerg, R., Welsh-Bohmerf, K., Zandia, P. P., &
Cache County Investigators. (2014). Use of diuretics is associated with reduced
risk of Alzheimer's disease: The Cache County Study. Neurobiology of
Aging, 35(11), 2429–2435. https://doi.org/10.1016/j.neurobiolaging.2014.05.002
Csukly, G., Sirály, E., Fodor, Z., Horváth, A., Salacz, P., Hidasi, Z., Csibri, E., Rudas, G.,
& Szabó, Á. (2016). The differentiation of amnestic type MCI from the nonamnestic types by structural MRI. Frontiers in Aging Neuroscience, 8,
52. https://doi.org/10.3389/fnagi.2016.00052
de Bruijn, R. F., & Ikram, M. A. (2014). Cardiovascular risk factors and future risk of
Alzheimer’s disease. BioMed Central, 12(1), 130. https://doi.org/10.1186/s12916014-0130-5
de la Torre, J. C. (2002). Alzheimer disease as a vascular disorder: Nosological evidence.
Stroke, 33(4), 1152–1162. https://doi.org/10.1161/01.STR.0000014421.15948.67
Ehrenkrantz, D., Silverman, J. M., Smith, C. J., Birstein, S., Marin, D., Mohs, R. C., &
Davis, K. L. (1999). Genetic epidemiological study of maternal and paternal
transmission of Alzheimer's disease. American Journal of Medical
Genetics, 88(4), 378–382. https://doi.org/10.1002/(SICI)10968628(19990820)88:4<378::AID-AJMG15>3.0.CO;2-8
Eriksson, U. K., Bennet, A. M., Gatz, M., Dickman, P. W., & Pedersen, N. L. (2010).
Non stroke cardiovascular disease and risk of Alzheimer’s disease and
dementia. Alzheimer Disease and Associated Disorders, 24(3), 213–219.
https://doi.org/10.1097/WAD.0b013e3181d1b99b
Fares, A. (2012). Use of beta-blockers and risk of dementia in elderly patients. The
Journal of Neuropsychiatry and Clinical Neurosciences, 24(4), E20–E21.
https://doi.org/10.1176/appi.neuropsych.11100240
Farrer, L. A., Cupples, L. A., Haines, J. L., Hyman, B., Kukull, W. A., Mayeux, R.,
Myers, R. H., Pericak-Vance, M. A., Risch, N., & Van Duijn, C. M. (1997).
Effects of age, sex, and ethnicity on the association between apolipoprotein E
genotype and Alzheimer disease: A meta-analysis. Journal of the American
Medical Association, 278(16), 1349–1356.
https://doi.org/10.1001/jama.1997.03550160069041
Fleisher, A., Grundman, M., Jack, C. R., Petersen, R. C., Taylor, C., Kim, H. T., Schiller,
D. H. B., Bagwell, V., Sencakova, D., Weiner, M. F., DeCarli, C., DeKosky, S.
T., van Dyck, C. H., Thal, L. J., & Alzheimer’s Disease Cooperative Study.
(2005). Sex, apolipoprotein E ε4 status, and hippocampal volume in mild
cognitive impairment. Archives of Neurology, 62(6), 953–957.
https://doi.org/10.1001/archneur.62.6.953

85
Fratiglioni, L., Ahlbom, A., Viitanen, M., & Winblad, B. (1993). Risk factors for late‐
onset Alzheimer's disease: A population‐based, case‐control study. Annals of
Neurology, 33(3), 258–266. https://doi.org/10.1002/ana.410330306
Frecker, M. F., Pryse-Phillips, W. E. M., & Strong, H. R. (1995). Alzheimer’s disease
death certificates. Neurology, 45(12), 2298–2298.
https://doi.org/10.1212/WNL.45.12.2298
Fryar, C. D., Ostchega, Y., Hales, C. M., Zhang, G., & Kruszon-Moran, D. (2017).
Hypertension prevalence and control among adults: United States, 2015–
2016. National Center of Health Statistics Data Brief, 289. Data Brief, Number
289, October 2017(cdc.gov).
Frost, J. (2020). Introduction to statistics: An intuitive guide for analyzing data and
unlocking discoveries (1st ed.). Jim Publishing.
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E., & Manson, J. E. (2016).
Cardiovascular disease in women: Clinical perspectives. Circulation
Research, 118(8), 1273–1293. https://doi.org/10.1161/circresaha.116.307547
Gottesman, R. F., Schneider, A. L., Zhou, Y., Coresh, J., Green, E., Gupta, N., Knopman,
D. S., Mintz, A., Rahmim, A., Sharrett, A. R., Wagenknecht, L. E., Wong, D. F.,
& Mosley, T. H. (2017). Association between midlife vascular risk factors and
estimated brain amyloid deposition. Journal of the American Medical
Association, 317(14), 1443–1450. https://doi.org/10.1001/jama.2017.3090
Guerreiro R., & Bras J. (2015). The age factor in Alzheimer’s disease. Genome
Medicine, 7(1), 1 3. https://doi.org/10.1186/s13073-015-0232-5
Hanson, H. A., Smith, K. R., & Zimmer, Z. (2015). Reproductive history and later-life
comorbidity trajectories: A Medicare-linked cohort study from the Utah
Population Database. Demography, 52(6), 2021–2049.
https://doi.org/10.1007/s13524-015-0439-5
Harman, S. M., Brinton, E. A., Cedars, M., Lobo, R., Manson, J. E., Merriam, G. R.,
Miller, V. M., Naftolin, F., & Santoro, N. (2005). KEEPS: The Kronos early
estrogen prevention study. Climacteric, 8(1), 3–12.
https://doi.org/10.1080/13697130500042417
Hayden, K. M., Zandi, P. P., Lyketsos, C. G., Khachaturian, A. S., Bastian, L. A.,
Charoonruk, Charoonruk, G., Tschanz, J. T., Norton, M., Pieper, C. F., Munger,
R. G., Breitner, J. C. S., & Welsh-Bohmer, K. A. (2006). Vascular risk factors for
incident Alzheimer disease and vascular dementia: The Cache County study.
Alzheimer Disease and Associated Disorders, 20(2), 93–100.
https://doi.org/10.1097/01.wad.0000213814.43047.86

86
Hayden, K. M., Zandi, P. P., West, N. A., Tschanz, J. T., Norton, M. C., Corcoran, C.,
Breitner, J. C. S., Welsh-Bohmer, K. A., & Cache County Study Group. (2009).
Effects of family history and apolipoprotein E ε4 status on cognitive decline in the
absence of Alzheimer dementia: The Cache County Study. Archives of
Neurology, 66(11), 1378–1383. https://doi.org/10.1001/archneurol.2009.237
Hebert, L. E., Scherr, P. A., McCann, J. J., Beckett, L. A., & Evans, D. A. (2001). Is the
risk of developing Alzheimer’s disease greater for women than for
men? American Journal of Epidemiology, 153(2), 132–
136. https://doi.org/10.1093/aje/153.2.132
Herskind, A. M., McGue, M., Holm, N. V., Sörensen, T. I., Harvald, B., & Vaupel, J. W.
(1996). The heritability of human longevity: A population-based study of 2872
Danish twin pairs born 1870–1900. Human Genetics, 97(3), 319–
323. https://doi.org/10.1007/BF02185763
Honea, R. A., Vidoni, E. D., Swerdlow, R. H., Burns, J. M., & Alzheimer’s Disease
Neuroimaging Initiative. (2012). Maternal family history is associated with
Alzheimer's disease biomarkers. Journal of Alzheimer's Disease, 31(3), 659–
668. https://doi.org/10.3233/JAD-2012-120676
Honig, L. S., Tang, M. X., Albert, S., Costa, R., Luchsinger, J., Manly, J., Stern, Y., &
Mayeux, R. (2003). Stroke and the risk of Alzheimer disease. Archives of
Neurology, 60(12), 1707–1712. https://doi.org/10.1001/archneur.60.12.1707
Jorm, A. F., & Jacomb, P. A. (1989). Informant questionnaire on cognitive decline in the
elderly (IQCODE): Socio-demographic correlates, reliability, validity, and some
norms. Psychological Medicine, 19(4), 1015–1022.
https://doi.org/10.1017/S0033291700005742
Jorm, A. F., & Jolley, D. (1998). The incidence of dementia: A metaanalysis. Neurology, 51(3), 728–733. https://doi.org/10.1212/WNL.51.3.728
Ju, Y.E. S., McLeland, J. S., Toedebusch, C. D., Xiong, C., Fagan, A. M., Duntley, S., …
Holtzman, D. M. (2013). Sleep quality and preclinical Alzheimer disease. Journal
of the American Medical Association Neurology, 70(5), 587–
593. https://doi.org/10.1001/jamaneurol.2013.2334
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016). Sex and gender differences in risk,
pathophysiology and complications of type 2 diabetes mellitus. Endocrine
Reviews, 37(3), 278–316. https://doi.org/10.1210/er.2015-1137
Kawas, C., Gray, S., Brookmeyer, R., Fozard, J., & Zonderman, A. (2000). Age-specific
incidence rates of Alzheimer’s disease: The Baltimore Longitudinal Study of
Aging. Neurology, 54(11), 2072–2077. https://doi.org/10.1212/WNL.54.11.2072

87
Lennon, M. J., Makkar, S. R., Crawford, J. D., & Sachdev, P. S. (2019). Midlife
hypertension and Alzheimer’s disease: A systematic review and metaanalysis. Journal of Alzheimer's Disease, 71(1), 307–
316. https://doi.org/10.3233/JAD-190474
Lipton, R. B., Hirsch, J., Katz, M. J., Wang, C., Sanders, A. E., Verghese, J., Barzilai, N.,
& Derby, C. A. (2010). Exceptional parental longevity associated with lower risk
of Alzheimer's disease and memory decline. Journal of the American Geriatrics
Society, 58(6), 1043–1049. https://doi.org/10.1111/j.1532-5415.2010.02868.x
Liu, Y., Paajanen, T., Westman, E., Wahlund, L. O., Simmons, A., Tunnard, C., Sobow,
T., proitsi, P., Powell, J., Mecocci, P., Tsolaki, M., Vellas, B., Muehlboech, S.,
Evans, A., Spenger, C., Lovestone, S., Soininen, H., & AddNeuroMed
Consortium. (2010). Effect of APOE ε4 allele on cortical thicknesses and
volumes: The AddNeuroMed study. Journal of Alzheimer's Disease, 21(3), 947–
966. https://doi.org/10.3233/jad-2010-100201
Lourida, I., Hannon, E., Littlejohns, T. J., Langa, K. M., Hyppönen, E., Kuźma, E., &
Llewellyn, D. J. (2019). Association of lifestyle and genetic risk with incidence of
dementia. Journal of the American Medical Association, 322(5), 430–
437. https://doi.org/10.1001/jama.2019.9879
Lüdecke, D., Ben-Shachar, M. S., Patil, I., Waggoner, P., & Makowski, D. (2021).
Performance: An R package for assessment, comparison and testing of statistical
models. The Journal of Open Source Software, 6(60),
3139. https://doi.org/10.21105/joss.03139
Luo, S., Valencia, C. A., Zhang, J., Lee, N. C., Slone, J., Gui, B., Wang, X., Li, Z., Dell,
S., Brown, J., Chen, S. M., Chien, Y.-H., Hwu, W.-L., Fan, P.-C., Wong, L.-J.,
Atwal, P. S., & Huang, T. (2018). Biparental inheritance of mitochondrial DNA
in humans. Proceedings of the National Academy of Sciences, 115(51), 13039–
13044. https://doi.org/10.1073/pnas.1810946115
Menze, B. H., Kelm, B. M., Masuch, R., Himmelreich, U., Bachert, P., Petrich, W., &
Hamprecht, F. A. (2009). A comparison of random forest and its Gini importance
with standard chemometric methods for the feature selection and classification of
spectral data. BioMed Central Bioinformatics, 10(1), 1–16.
https://doi.org/10.1186/1471-2105-10-213
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M.
(1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDSADRDA work group under the auspices of Department of Health and Human
Services task force on Alzheimer’s disease. Neurology, 34 (7), 939–
44. https://doi.org/10.1212/wnl.34.7.939

88
Miech, R. A., Breitner, J. C., Zandi, P. P., Khachaturian, A. S., Anthony, J. C., & Mayer,
L. (2002). Incidence of AD may decline in the early 90s for men, later for women:
The Cache County study. Neurology, 58(2), 209–218.
https://doi.org/10.1212/WNL.58.2.209
Mielke, M. M., Vemuri, P., & Rocca, W. A. (2014). Clinical epidemiology of
Alzheimer’s disease: Assessing sex and gender differences. Clinical
Epidemiology, 6, 37–48. https://doi.org/10.2147/clep.S37929
Mosca, L., Barrett-Connor, E., & Kass Wenger, N. (2011). Sex/gender differences in
cardiovascular disease prevention: What a difference a decade makes.
Circulation, 124(19), 2145–2154.
https://doi.org/10.1161/circulationaha.110.968792
Mosconi, L., Berti, V., Swerdlow, R. H., Pupi, A., Duara, R., & de Leon, M. (2010).
Maternal transmission of Alzheimer's disease: Prodromal metabolic phenotype
and the search for genes. Human Genomics, 4(3), 170–193.
https://doi.org/10.1186/1479-7364-4-3-170
Mosconi, L., Brys, M., Switalski, R., Mistur, R., Glodzik, L., Pirraglia, E., Tsui, W., De
Santi, S., & de Leon, M. J. (2007). Maternal family history of Alzheimer's disease
predisposes to reduced brain glucose metabolism. Proceedings of the National
Academy of Sciences, 104(48), 19067–19072.
https://doi.org/10.1073/pnas.0705036104
Mueller, K., Thiel, F., Beutner, F., Teren, A., Frisch, S., Ballarini, T., Möller, H. E., Ihle,
K., Thiery, J., Schuler, G., Villringer, A., & Schroeter, M. L. (2020). Brain
damage with heart failure: Cardiac biomarker alterations and gray matter decline.
Circulation Research, 126(6), 750–764.
https://doi.org/10.1161/circresaha.119.315813
Nair, R., Haynes, V. S., Siadaty, M., Patel, N. C., Fleisher, A. S., Van Amerongen, D.,
Witte, M., Downing, A. M., Fernandez, L. A. H., Saundankar, V., & Ball, D. E.
(2018). Retrospective assessment of patient characteristics and healthcare costs
prior to a diagnosis of Alzheimer’s disease in an administrative claims database.
BioMed Central Geriatrics, 18(243), 1–12. https://doi.org/10.1186/s12877-0180920-2
Nebel, R. A., Aggarwal, N. T., Barnes, L. L., Gallagher, A., Goldstein, J. M., Kantarci,
K., Mallampalli, M. P., Mormino, E. C., Scott, L., Yu, W. H., Maki, P. M., &
Mielke, M.. (2018). Understanding the impact of sex and gender in Alzheimer's
disease: A call to action. Alzheimer's & Dementia, 14(9), 1171–1183.
https://doi.org/10.1016/j.jalz.2018.04.008

89
Norton, M. C., Fauth, E., Clark, C. J., Hatch, D., Greene, D., Pfister, R., … Smith, K. R.
(2016). Family member deaths across adulthood predict Alzheimer's disease risk:
The Cache County Study. International Journal of Geriatric Psychiatry, 31(3),
256–263. https://doi.org/10.1002/gps.4319
Patel, M. J., de Lemos, J. A., Philips, B., Murphy, S. A., Vaeth, P. C., McGuire, D. K., &
Khera, A. (2007). Implications of family history of myocardial infarction in
young women. American heart journal, 154(3), 454–460.
https://doi.org/10.1016/j.ahj.2007.05.016
Passarino, G., De Rango, F., & Montesanto, A. (2016). Human longevity: Genetics or
Lifestyle? It takes two to tango. Immunity and Ageing, 13(12), 1–6.
https://doi.org/10.1186/s12979016-0066-z
Payami, H., Zareparsi, S., Montee, K. R., Sexton, G. J., Kaye, J. A., Bird, T. D., Yu, C.
E., Wijsman, E. M., Heston, L. L., Litt, M., & Schellenberg, G. D. (1996). Gender
difference in apolipoprotein E-associated risk for familial Alzheimer disease: A
possible clue to the higher incidence of Alzheimer disease in women. American
Journal of Human Genetics, 58(4), 803–811. PMCID:PMC1914663.
Perls, T., Shea-Drinkwater, M., Bowen-Flynn, J., Ridge, S. B., Kang, S., Joyce, E., Daly,
M., Brewster, S. J., Kunkel, L., & Puca, A. A. (2000). Exceptional familial
clustering for extreme longevity in humans. Journal of the American Geriatrics
Society, 48(11), 1483–1485. https://doi.org/10.1111/jgs.2000.48.11.1483
Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of
Internal Medicine, 256(3), 183–194. https://doi.org/10.1111/j.13652796.2004.01388.x
Raiford, K., Anton-Johnson, S., Haycox, Z., Nolan, K., Schaffer, A., Caimano, C.,
Fillenbaum, G., & Heyman, A. (1994). CERAD: VII. Accuracy of reporting
dementia on death certificates of patients with Alzheimer's
disease. Neurology, 44(11), 2208–2209. https://doi.org/10.1212/wnl.44.11.2208-a
Revelle, W. (2020). psych: Procedures for Personality and Psychological Research.
Northwestern University, Evanston, https://CRAN.r-project.org/package=psych.
R package version 2.0.8
Roberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F.,
Tangalos, E. G., Ivnik, R. J., Rocca, W. A., & Petersen, R. C. (2012). The
incidence of MCI differs by subtype and is higher in men: The Mayo Clinic Study
of Aging. Neurology, 78(5), 342–351.
https://doi.org/10.1212/WNL.0b013e3182452862

90
Robinson, J. L., Porta, S., Garrett, F. G., Zhang, P., Xie, S. X., Suh, E., Van Deerlin, V.
M., Abner, E. L., Jicha, G. A., Barber, J. M., Lee, V. M.-Y., Lee, E. B.,
Trojanowski, J. Q., & Nelson, P. T. (2020). Limbic-predominant age-related
TDP-43 encephalopathy differs from frontotemporal lobar
degeneration. Brain, 143(9), 2844–2857. https://doi.org/10.1093/brain/awaa219
Rodgers, J. L., Jones, J., Bolleddu, S. I., Vanthenapalli, S., Rodgers, L. E., Shah, K.,
Karia, K., & Panguluri, S. K. (2019). Cardiovascular Risks Associated with
Gender and Aging. Journal of Cardiovascular Development and Disease, 6(2),
19. https://doi.org/10.3390/jcdd6020019
Román, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia,
J. H., … Scheinberg, P. (1993). Vascular dementia: Diagnostic criteria for
research studies; report of the ninds-airen international
workshop. Neurology, 43(2), 250–260. https://doi.org/10.1212/wnl.43.2.250
RStudio Team (2021). RStudio: Integrated Development for R. RStudio, PBC, Boston,
MA URL http://www.rstudio.com/
Sebastiani, P., Solovieff, N., DeWan, A. T., Walsh, K. M., Puca, A., Hartley, S. W.,
Melista, E., Andersen, S., Dworkis, D. A., Wilk, J. B., Myers, R. H., Steinberg,
M. H., Montano, M., Baldwin, C. T., Hoh, J., & Perls, T. T. (2012). Genetic
signatures of exceptional longevity in humans. Public Library of Science One,
7(1), e29848. https://doi.org/10.1371/journal.pone.0029848
Shay, C. M., Gooding, H. S., Murillo, R., & Foraker, R. (2015). Understanding and
improving cardiovascular health: An update on the American Heart Association's
concept of cardiovascular health. Progress in Cardiovascular Diseases, 58(1),
41–49. https://doi.org/10.1016/j.pcad.2015.05.003
Shumaker, S. A., Reboussin, B. A., Espeland, M. A., Rapp, S. R., McBee, W. L., Dailey,
M., Bowen, D., Terrell, T., & Jones, B., N.. (1998). The Women’s Health
Initiative Memory Study (WHIMS): A trial of the effect of estrogen therapy in
preventing and slowing the progression of dementia. Controlled Clinical
Trials, 19(6), 604–621. https://doi.org/10.1016/S0197-2456(98)00038-5
Sjögren, M., & Blennow, K. (2005). The link between cholesterol and Alzheimer's
disease. The World Journal of Biological Psychiatry, 6(2), 85–97.
https://doi.org/10.1080/15622970510029795
Soto, M. E., Abellan van Kan, G., Nourhashemi, F., Gillette‐Guyonnet, S., Cesari, M.,
Cantet, C., Rolland, Y., & Vellas, B. (2013). Angiotensin‐converting enzyme
inhibitors and Alzheimer's disease progression in older adults: Results from the
réseau sur la maladie d'Alzheimer français cohort. Journal of the American
Geriatrics Society, 61(9), 1482–1488. https://doi.org/10.1111/jgs.12415

91
Strub, R. L. (2003). Vascular dementia. Ochsner Journal, 5(1), 40–43.
https://doi.org/ 10.1097/01.SMJ.0000063470.95541.6B
Sundbøll, J., Horváth-Puhó, E., Adelborg, K., Schmidt, M., Pedersen, L., Bøtker, H. E.,
... & Toft,Sørensen, H. (2018). Higher risk of vascular dementia in myocardial
infarction survivors. Circulation, 137(6), 567–577.
https://doi.org/10.1161/circulationaha.117.029127
Sundermann, E. E., Maki, P. M., Rubin, L. H., Lipton, R. B., Landau, S., Biegon, A., &
Alzheimer's Disease Neuroimaging Initiative. (2016). Female advantage in verbal
memory: Evidence of sex-specific cognitive reserve. Neurology, 87(18), 1916–
1924. https://doi.org/10.1212/WNL.0000000000003288
Tang, M. X., Jacobs, D., Stern, Y., Marder, K., Schofield, P., Gurland, B., ... & Mayeux,
R. (1996). Effect of oestrogen during menopause on risk and age at onset of
Alzheimer's disease. The Lancet, 348(9025), 429–
432. https://doi.org/10.1016/S0140-6736(96)033569
Teng, E. L., & Chui, H. C. (1987). The Modified Mini-Mental State (3MS)
examination. The Journal of Clinical Psychiatry, 48(8), 314-8. PMID: 3611032.
Tibshirani, R. (1996). Regression shrinkage and selection via the lasso. Journal of the
Royal Statistical Society: Series B (Methodological), 58(1), 267–
288. https://doi.org/10.1111/j.2517-6161.1996.tb02080.x
Tolnay, M., & Clavaguera, F. (2004). Argyrophilic grain disease: A late‐onset dementia
with distinctive features among tauopathies. Neuropathology, 24(4), 269–
283. https://doi.org/10.1111/j.1440-1789.2004.00591.x
Touzé, E., & Rothwell, P. M. (2007). Heritability of ischaemic stroke in women
compared with men: A genetic epidemiological study. The Lancet
Neurology, 6(2), 125–133. https://doi.org/10.1016/S1474-4422(06)70683-4
Tschanz, J. T., Norton, M. C., Zandi, P. P., & Lyketsos, C. G. (2013). The Cache County
Study on Memory in Aging: Factors affecting risk of Alzheimer’s disease and its
progression after onset. International Review of Psychiatry, 25(6), 673–
685. https://doi.org/10.3109/09540261.2013.849663
Tschanz, J. T., Welsh-Bohmer, K. A., Plassman, B. L., Norton, M. C., Wyse, B. W.,
Breitner, J. C., & Cache County Study Group. (2002). An adaptation of the
modified mini-mental state examination: Analysis of demographic influences and
normative data: The cache county study. Neuropsychiatry, Neuropsychology, and
Behavioral Neurology, 15(1), 28–38. PMID: 11877549

92
van Duijn, C. M., Clayton, D., Chandra, V., Fratiglioni, L., Graves, A. B., Heyman, A., ...
Rocca, W. A. (1991). Familial aggregation of Alzheimer's disease and related
disorders: A collaborative re-analysis of case-control studies. International
Journal of Epidemiology, 20(Supplement_2), S13–
S20. https://doi.org/10.1093/ije/20.Supplement_2.S13
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson,
A. P., ... & American Heart Association Council on Epidemiology and Prevention
Statistics Committee and Stroke Statistics Subcommittee. (2020). Heart disease
and stroke statistics—2020 update: A report from the American Heart
Association. Circulation, 141(9), e139–
e596. https://doi.org/10.1161/CIR.0000000000000757
Wallace, D. C. (2005). A mitochondrial paradigm of metabolic and degenerative
diseases, aging, and cancer: A dawn for evolutionary medicine. Annual Reviews
of Genetics, 39, 359–
407. https://doi.org/10.1146/annurev.genet.39.110304.095751
Westendorp, R. G., Van Heemst, D., Rozing, M. P., Frölich, M., Mooijaart, S. P., Blauw,
G. J., ... & Leiden Longevity Study Group. (2009). Nonagenarian siblings and
their offspring display lower risk of mortality and morbidity than sporadic
nonagenarians: The Leiden Longevity Study. Journal of the American Geriatrics
Society, 57(9), 1634–1637. https://doi.org/10.1111/j.1532-5415.2009.02381.x
Whitmer, R. A., Quesenberry, C. P., Zhou, J., & Yaffe, K. (2011). Timing of hormone
therapy and dementia: The critical window theory revisited. Annals of
Neurology, 69(1), 163–169. https://doi.org/10.1002/ana.22239
Yaffe, K., Falvey, C. M., & Hoang, T. (2014). Connections between sleep and cognition
in older adults. The Lancet Neurology, 13(10), 1017–
28. http://doi.org/10.1016/ S14744422(14)70172-3
Zandi, P. P., Sparks, D. L., Khachaturian, A. S., Tschanz, J., Norton, M., Steinberg, M.,
... & Cache County Study investigators. (2005). Do statins reduce risk of incident
dementia and Alzheimer disease? the Cache County Study. Archives of General
Psychiatry, 62(2), 217–224. http://doi.org/10.1001/archpsyc.62.2.217
Zandi, P. P., Carlson, M. C., Plassman, B. L., Welsh-Bohmer, K. A., Mayer, L. S.,
Steffens, D. C., ... & Cache County Memory Study Investigators. (2002).
Hormone replacement therapy and incidence of Alzheimer disease in older
women: The Cache County Study. Journal of the American Medical
Association, 288(17), 2123–2129. https://doi.org/ doi:10.1001/jama.288.17.2123

93

Appendices

94
Appendix A: Family History Interview

95

96

97

98

99
Appendix B: Medical History Questionnaire

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117
Appendix C: Direct Maternal and Paternal Lineage Diagram
Figure C.1
Direct Maternal and Paternal Lineage Diagram
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Appendix D: Tetrachoric Correlation Matrix, Random Forest
Analyses, and Lasso Regression Output
Table D.1
Tetrachoric Correlation Matrix

CHF CVA DM MI
CHF
CVA
DM
MI
CHOL
HTN
AFIB
ATHERO
OBESE
HYPO
DYSRHY

1.00
0.23
0.22
0.28
0.04
0.22
0.61
0.44
0.47
0.40
0.54

0.23
1.00
0.20
0.21
0.10
0.26
0.25
0.30
0.19
0.20
0.25

0.22
0.20
1.00
0.24
0.16
0.34
0.13
0.17
0.36
0.10
0.16

CHOL HTN AFIB ATHERO OBESE HYPO DYSRHY

0.28
0.21
0.24
1.00
0.29
0.17
0.17
0.08
0.21
0.06
0.19

0.04
0.10
0.16
0.29
1.00
0.28
0.09
0.19
0.19
0.18
0.17

0.22
0.26
0.34
0.17
0.28
1.00
0.28
0.34
0.41
0.23
0.33

0.61
0.25
0.13
0.17
0.09
0.28
1.00
0.59
0.33
0.68
0.83

0.44
0.30
0.17
0.08
0.19
0.34
0.59
1.00
0.44
0.61
0.66

0.47
0.19
0.36
0.21
0.19
0.41
0.33
0.44
1.00
0.50
0.50

0.40
0.20
0.10
0.06
0.18
0.23
0.68
0.61
0.50
1.00
0.71

0.54
0.25
0.16
0.19
0.17
0.33
0.83
0.66
0.50
0.71
1.00

Table D.2
Tetrachoric Correlation Matrix With Combined Atrial Fibrillation and Dysthymias

CHF
CVA
DM
MI
CHOL
HTN
ATHERO
OBESE
HYPO
RHYTHMIAS

CHF

CVA

1.00
0.27
0.17
0.27
0.02
0.25
0.50
0.55
0.49
0.66

0.27
1.00
0.13
0.20
0.08
0.23
0.35
0.12
0.26
0.33

DM
0.17
0.13
1.00
0.24
0.15
0.32
0.18
0.35
0.11
0.17

MI
0.27
0.20
0.24
1.00
0.25
0.15
0.08
0.24
0.07
0.23

CHOL

HTN

0.02
0.08
0.15
0.25
1.00
0.26
0.19
0.23
0.18
0.14

0.25
0.23
0.32
0.15
0.26
1.00
0.34
0.51
0.23
0.33

ATHERO
0.50
0.35
0.18
0.08
0.19
0.34
1.00
0.51
0.59
0.65

OBESE
0.55
0.12
0.35
0.24
0.23
0.51
0.51
1.00
0.59
0.62

HYPO
0.49
0.26
0.11
0.07
0.18
0.23
0.59
0.59
1.00
0.69

RHYTHMIAS
0.66
0.33
0.17
0.23
0.14
0.33
0.65
0.62
0.69
1.00
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Table D.3
Tetrachoric Correlation Matrix With Collapsed Cholesterol/Atherosclerosis and Atrial
Fibrillation and Other Dysrhythmias
CHF CVA DM MI
CHF
CVA
DM
MI
CHOL/ATHERO
HTN
OBESE
HYPO
RHYTHMIAS

1.00
0.27
0.17
0.26
-0.02
0.28
0.53
0.52
0.67

0.27
1.00
0.16
0.26
0.11
0.26
0.16
0.27
0.31

0.17
0.16
1.00
0.31
0.15
0.33
0.31
0.12
0.13

0.26
0.26
0.31
1.00
0.17
0.22
0.27
0.13
0.16

CHOL/ATHERO
-0.02
0.11
0.15
0.17
1.00
0.22
0.22
0.14
0.07

HTN OBESE
0.28
0.26
0.33
0.22
0.22
1.00
0.47
0.15
0.32

Table D.4
Variance Inflation Factors Analysis for Research Question 4
Variable
Sex
Age
Education
Ethnicity
APOE Ɛ4 Allele
Direct Maternal Lineage
Direct Paternal Linage
CHF
CVA
DM
MI
HTN
Obesity
Cholesterol/Atherosclerosis
Hypothyroidism
Atrial Fibrillation and Other Dysrhythmias
Note. The cutoff for variance inflation is 5.

Variance Inflation Factors
1.05
1.19
1.03
1.01
1.07
1.03
1.03
1.03
1.02
1.04
1.06
1.08
1.00
1.12
1.00
1.00

0.53
0.16
0.31
0.27
0.22
0.47
1.00
0.59
0.59

HYPO RHYTHMIAS
0.52
0.27
0.12
0.13
0.14
0.15
0.59
1.00
0.71

0.67
0.31
0.13
0.16
0.07
0.32
0.59
0.71
1.00
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Table D.5
Female: Random Forest Analysis Output for Research Question 4
Variable
Age at Baseline
Education
Ethnicity
APOE Ɛ4 Status
Direct Maternal Lineage
Direct Paternal Lineage
Congestive Heart Failure
Cerebrovascular Accident
Diabetes Mellitus
Myocardial Infarction
Hypertension
Obesity
Cholesterol/Atherosclerosis
Hypothyroidism
Atrial Fibrillation and Other Dysrhythmias

Mean Decrease in Gini
127.68
9.63
1.83
37.47
7.84
7.20
50.19
9.16
8.34
7.16
10.79
5.87
10.12
101.75
96.69

Table D.6
Male: Random Forest Analysis Output for Research Question 4
Variable
Age at Baseline
Education
Ethnicity
APOE Ɛ4 Status
Direct Maternal Lineage
Direct Paternal Lineage
Congestive Heart Failure
Cerebrovascular Accident
Diabetes Mellitus
Myocardial Infarction
Hypertension
Obesity
Cholesterol/Atherosclerosis
Hypothyroidism
Atrial Fibrillation and Other Dysrhythmias

Mean Decrease in Gini
74.44
7.86
0.94
18.79
4.90
3.86
29.17
4.92
5.37
6.85
6.77
0.60
6.29
34.51
96.83
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Figure D.1
Female: Random Forest Plot for Importance of Variable for Model Prediction

Note. Gender/sex is not predictive as this is a stratified model and males were removed. v1age = Age at
baseline; predem_hypothy_medclm = hypothyroidism;predem_rhythmias_medclm = Atrial fibrillation and
other dysrhythmias; predem_chf_ccms_claim = congestive heart failure; apoe4= APOE Ɛ4 status;
predem_htn_ccms_claim = hypertension; educ2 = education; predem_cva_ccms_claim = cerebrovascular
accident; predem_dm_ccms_claim = diabetes mellitus; dc_ccms_maternalfamhx = Direct Maternal Lineage
of AD; dc_ccms_paternalfamhx = direct paternal lineage of AD; predem_mi_ccms_claim = myocardial
infarction; predem_obesity_medclm = obesity; ethnic = ethnicity; gender = sex.
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Figure D.2
Male: Random Forest Plot for Importance of Variable for Model Prediction

Note. Gender/sex is not predictive as this is a stratified model and females were removed. v1age = Age at
baseline; predem_hypothy_medclm = hypothyroidism; predem_rhythmias_medclm = Atrial fibrillation and
other dysrhythmias; predem_chf_ccms_claim = congestive heart failure; apoe4 = APOE Ɛ4 status;
predem_htn_ccms_claim = hypertension; educ2 = education; predem_cva_ccms_claim = cerebrovascular
accident; predem_dm_ccms_claim = diabetes mellitus; dc_ccms_maternalfamhx = Direct Maternal Lineage
of AD; dc_ccms_paternalfamhx = direct paternal lineage of AD; predem_mi_ccms_claim = myocardial
infarction; predem_obesity_medclm = obesity; ethnic = ethnicity; gender = sex.
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Table D.7
LASSO Regression Analysis With Lambda Set at 0.09 for Research Question 4
Variable
Intercept
Sex
Age at Baseline
Education
APOE Ɛ4 Status
Direct Maternal Lineage of AD
Direct Paternal Lineage of AD
Congestive Heart Failure
Cerebrovascular Accident
Diabetes Mellitus
Myocardial Infarction
Hypertension
Obesity
Cholesterol/Atherosclerosis
Hypothyroidism
Atrial Fibrillation and Other Dysrhythmias

LASSO Coefficient
-4.78
—
0.01
—
0.00
—
—
0.26
—
—
—
—
—
—
1.04
1.57

Table D.8
LASSO Regression Analysis With Cross-Validation Lambda
Variable
Intercept
Sex
Age at Baseline
Education
APOE Ɛ4 Status
Direct Maternal Lineage of AD
Direct Paternal Lineage of AD
Congestive Heart Failure
Cerebrovascular Accident
Diabetes Mellitus
Myocardial Infarction
Hypertension
Obesity
Cholesterol/Atherosclerosis
Hypothyroidism
Atrial Fibrillation and Other Dysrhythmias

LASSO Coefficient
20.92
-0.09
-0.09
—
-1.14
-0.04
-0.11
-1.45
-0.21
0.02
0.47
—
-0.94
—
-4.10
-4.42
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Appendix E: Male and Female Binary Logistic
Regression Nonsignificant Interactions
Table E.1
Female: Binary Logistic Regression Cardiovascular Risk Factors by Direct Maternal
and Paternal Lineage of Alzheimer’s Disease
Parameter

β

Congestive Heart Failure × DMLAD
Cerebrovascular Accident × DMLAD
Cerebrovascular Accident × DPLAD
Diabetes Mellitus × DMLAD
Diabetes Mellitus × DPLAD
Myocardial Infarction × DMLAD
Myocardial Infarction × DPLAD
Hypertension × DMLAD
Hypertension × DPLAD
Cholesterol/Triglycerides/Atherosclerosis × DMLAD
Cholesterol/Triglycerides/Atherosclerosis × DPLAD
Hypothyroidism × DMLAD
Hypothyroidism × DPLAD
Obesity × DMLAD
Obesity × DPLAD
Atrial Fibrillation and Other Dysrhythmias × DMLAD
Atrial Fibrillation and Other Dysrhythmias × DPLAD

0.54
0.51
-0.69
-0.50
-0.17
-0.15
-0.59
0.20
0.22
-0.42
0.79
-0.52
-0.14
0.26
NA
-0.38
-0.22

SE
0.71
0.48
0.73
0.48
0.55
0.50
0.87
0.33
0.45
0.32
0.45
871.4
1427.0
821.1
NA
906.4
1209

Wald
0.76
1.05
-0.95
-1.05
-0.31
-0.31
-0.70
0.33
0.45
-1.30
1.77
-0.0006
-0.0001
0.0003
NA
-0.0004
-0.0002

df

Sig.

Exp(β)

1
1
1
1
1
1
1
1
1
1
1
1
1
1
—
1
1

.445
.300
.344
.295
.760
.760
.500
.552
.635
.192
.076
.999
.999
.997
NA
.999
.999

1.72
1.66
0.50
0.60
0.84
0.86
0.55
1.22
1.24
-0.42
2.21
0.59
0.87
1.29
NA
0.68
0.81

Note. Each cardiovascular risk factor by direct maternal and paternal lineage of AD is from a different
binary logistic regression. AD = Alzheimer’s Disease; DMLAD = Direct Maternal Lineage of AD; DPLAD
= Direct Paternal Lineage of AD.
*p < .05. **p < .001.
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Table E.2
Male: Binary Logistic Regression Cardiovascular Risk Factors by Direct Maternal and
Paternal Lineage of Alzheimer’s Disease
Parameter

β

Congestive Heart Failure × DMLAD
Congestive Heart Failure × DPLAD
Cerebrovascular Accident × DMLAD
Cerebrovascular Accident × DPLAD
Diabetes Mellitus × DMLAD
Diabetes Mellitus × DPLAD
Myocardial Infarction × DMLAD
Myocardial Infarction × DPLAD
Hypertension × DMLAD
Hypertension × DPLAD
Cholesterol/Triglycerides/Atherosclerosis × DMLAD
Cholesterol/Triglycerides/Atherosclerosis × DPLAD
Hypothyroidism × DMLAD
Hyperthyroidism × DPLAD
Obesity × DMLAD
Obesity × DPLAD
Atrial Fibrillation and Other Dysrhythmias × DMLAD
Atrial Fibrillation and Other Dysrhythmias × DPLAD

-0.22
1.13
-1.38
0.12
0.10
-0.50
0.39
0.56
-0.15
0.78
0.05
0.23
-0.19
-0.23
NA
0.16
-0.11
-0.31

SE
0.91
1.22
0.76
0.98
0.46
0.68
0.47
0.69
0.42
0.60
0.40
0.54
983.34
1617.26
NA
655.67
1020.51
1955.38

Wald
-0.25
0.93
-1.82
0.12
0.21
-0.73
0.83
0.82
-0.35
1.30
0.14
0.42
-0.0002
-0.0001
NA
0.0003
-0.0001
-0.0002

df

Sig.

Exp(β)

1
1
1
1
1
1
1
1
1
1
1
1
1
1
—
1
1
1

.805
.353
.069
.901
.833
.463
.404
.413
.725
.193
.884
.671
.999
.999
NA
.999
.999
.999

0.80
3.11
0.48
0.12
1.10
0.61
1.48
1.76
0.86
2.19
1.25
1.30
0.83
1.27
NA
1.18
0.89
1.37

Note. Each cardiovascular risk factor by direct maternal and paternal lineage of AD is from a different
binary logistic regression. AD = Alzheimer’s Disease; DMLAD = Direct Maternal Lineage of AD; DPLAD
= Direct Paternal Lineage of AD.
*p < .05. **p < .001.
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Appendix F: Male: Binary Logistic Regression Trend Level Interaction
for Cerebrovascular Accident and Direct Maternal
Lineage of Alzheimer’s Disease
Table F.1
Male: Binary Logistic Regression for Cerebrovascular Accident and Maternal Family
Lineage of Alzheimer’s Disease
OR 95% CI
Parameter
Intercept
Congestive Heart Failure
Cerebrovascular Accident
Hypertension
Cholesterol/Triglycerides/
Atherosclerosis
APOE Ɛ4 Status
Direct Maternal Lineage of AD
Direct Paternal Lineage of AD
Education
Age
Direct Maternal Lineage of AD
× Cerebrovascular Accident

Note. AD = Alzheimer’s Disease.
*p < .05. **p < .001.

b

SE

Wald

df

-9.77
2.37
0.69
0.30
0.41

0.91
0.26
0.23
0.15
0.15

-10.76
9.04
3.02
2.07
2.63

1
1

1.28
0.28
0.30
0.07
0.09
-1.38

0.15
0.22
0.28
0.15
0.01
0.52

8.57
1.30
1.09
0.45
8.56
-1.82

1
1
1
1
1
1

1

Sig.

OR

<0.001** <0.001
<0.001** 11.71
0.002*
1.99
0.04*
1.36
0.001*
1.50
<0.001**
0.19
0.28
0.65
<0.001**
0.07

3.60
1.33
1.35
1.07
1.10
0.25

Lower

Upper

<0.001
6.47
1.26
1.02
1.11

<0.001
11.82
3.09
1.83
2.04

2.69
0.86
0.77
0.80
1.07
0.48

4.84
2.03
2.30
1.43
1.12
1.01
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Figure F.1
Males With History of Cerebrovascular Accident and Direct Maternal Lineage and Risk
for Alzheimer’s Disease

Note. This figure presents a probability plot male probands with a direct maternal lineage of AD by history
of a cerebrovascular accident (CVA) across various ages for male probands without the presence of an
APOE Ɛ4 allele, without a history of hypertension or cholesterol/triglycerides/atherosclerosis or congestive
heart failure and with a high school/GED/or less education. This model was not retained as it was not the
most parsimonious and did not have the lowest AIC, BIC, and R-squared compared to the model presented
in cardiovascular risk factors with family history and Alzheimer’s disease among male probands section.
AD = Alzheimer’s Disease.
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Oral and Poster Presentations
Vernon, E.K., Rattinger, G.B., DeBerard, M.S., Kugler, J., & Tschanz, J.T. (July 2019).
Sex Differences in the Association between Sleep Medications and Risk of
Alzheimer’s Disease: The Cache County Study (USA). Poster Presentation at the
Alzheimer’s Association International Conference, Los Angeles, CA
Hammond, A.G., Vernon, E.K., Kauzor, K.E., Tschanz, J.T. (July 2019). Baseline
Cognitive Status and Conversion to Alzheimer’s Disease Based on Gender: The
Cache County Memory Study. Poster Presentation at the Alzheimer’s Association
International Conference, Los Angeles, CA
Tschanz, J.T., Vernon, E.K., Kauzor, K.E., Hammond, A.G., Corcoran, C., CannonAlbright, L., Teerlink, C., & Kauwe, J.S. (July 2019). Risk of Alzheimer’s
Disease and Related Dementias varies by Maternal, Paternal, and Sibling Family
History & Sex: The Cache County Study. Poster Presentation at the Alzheimer’s
Association International Conference, Los Angeles, CA
Vernon, E.K., Behrens, S., Rattinger, G.B., Schwartz, S., & Tschanz, J.T. (July 2018).
Use of Sleep Medications is Associated with Poorer Cognition in Older Male
Adults: The Cache County Study (USA). Poster Presentation at the Alzheimer’s
Association International Conference, Chicago, IL
Mayti, J., West, N., Rattinger, G.B., Vernon, E.K., Buhusi, M., & Tschanz, J.T. (July
2018). Reproductive Window and Moderating Factors Associated with Risk for
Alzheimer’s Disease: The Cache County Study. Poster presentation at the
Alzheimer’s Association International Conference, Chicago, IL
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Vernon, E.K., Cooley, B., Rozum, W., Rattinger, G.B., Behrens, S., Fauth, B., &
Tschanz, J.T. (July 2017). Caregiver-Care Recipient Relationships are Associated
with Neuropsychiatric Symptoms in Dementia. Poster presentation at
International Association of Gerontology and Geriatrics, San Francisco, CA
Rozum, W., Cooley, B., Vernon, E.K., Richens, A., Mayti, J., & Tschanz, J.T. (April
2017). Specific Cognitive/Behavioral Domains Predict Neuropsychiatric
Symptoms in Severe Dementia. Poster presentation at Rocky Mountain
Psychological Association, Salt Lake City, UT
DeBerard, M.S., Rattinger, G., Marley, M., Cooley, B., Sanders, C., Behrens, S., Vernon,
E.K., & Tschanz, J.T. (March 2017). Self-Rated Health Predicts Mortality in
Older Adults Regardless of Cognitive Status. Poster Presentation at Society of
Behavioral Medicine, San Diego, CA
Vernon, E.K., Behrens, S. B., Mayti, J., & Tschanz, J.T. (January 2016). Sleep
Disturbances and Their Association with Cognitive Status in a Population Based
Sample of Older Adults: The Cache County Memory Study. Poster presentation at
the International Neuropsychology Society, New Orleans, LA
Mayti, J., Rattinger, G.B., Sanders, C., Vernon, E.K., Corcoran, C., Kauwe, J.K.,
Buhusi, M., & Tschanz, J.T. (November 2016). Sex Differences in Neurotrophin
Genes and Risk for Alzheimer’s Disease. Poster presentation at Gerontological
Society of America, New Orleans, LA
Tschanz, J.T., Rattinger, G.B., Marley, M., Cooley, B., Sanders, C., Behrens, S., Vernon,
E.K., & DeBerard, M.S. (November 2016). Self-Rated Health Predicts Mortality
in Older Adults Regardless of Cognitive Status. Poster presentation at the
Gerontological Society of America, New Orleans, LA
Babulal, G.M., Vernon, E.K., Ghoshal, N., Head, D.M., Carr, D.B., Barco, P., Morris,
J.C., & Roe, C.M. (November 2015). Stress and Driving Errors in Older Adults
with and without Preclinical Alzheimer’s Disease. Poster Presentation at the
Gerontological Society of America, Orlando, FL
Vernon, E.K., Babulal, G.M., Head, D., Wallendorf, M., Carr, D.B, Ghoshal, N., Barco,
P.P., Morris, J.C., & Roe, C.M. Adults 65 and Older Use Potentially Distracting
Electronic Devices while Driving. Poster presentation at the Alzheimer’s
Association International Conference, Washington, D.C.
Babulal, G.M., Vernon, E.K., Ghoshal, N., Head, D.M., Barco, P.P., Carr, D.B., Morris,
J.C., & Roe, C.M. (July 2015). Poster Presentation at the Alzheimer’s Association
International Conference, Washington, D.C.
Roe, C.M., Barco, P.P., Head, D.M., Ghoshal, N., Selsor, N., Babulal, G.M., Fierberg, R.,
Vernon, E.K., Shulman, N., Johnson, A., Fague, S., Xiong, C., Grant, E.A.,
Campbell, A., Holtzman, D.M., Benzinger, T., Fagan, A.M., Carr, D.B., Morris,
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J.C. (July 2015). Amyloid Imaging and Cerebrospinal Fluid Biomarkers Predict
Driving Performance in Preclinical Alzheimer’s Disease. Poster presentation at
the Alzheimer’s International Conference, Washington, D.C.
Ruvolo, D., Chasse, R., Vernon, E.K., Maue-Dreyfus, D., Grant, E., Morris, J.C., &
Hassenstab, J. (July 2013). Attenuation of Practice Effects is a Potential Marker
of Pre-Clinical Alzheimer’s Disease. Poster Presentation at the Alzheimer’s
Association International Conference, Boston, MA
Vernon, E.K., Sweet, L., McCaffery, J., Phelan, S., McDermott, K., Cohen, R.A., Wing,
R.R., & Hassenstab, J. (April 2013). Neural Response to High-Calorie Food
Words in Obesity and Successful Weight Loss Maintenance. Poster Presentation
at the Cognitive Neuroscience Society Conference, San Francisco, CA
Research Press Releases/Press Articles
Interviewee (February 2020)
• Sleep Medication in Older Adults. ALZ magazine.
Presenter (July 2019)
• Sleep Drugs, Sex Differences in the Association between Sleep Medication and
Risk of Alzheimer’s Disease: The Cache County Study, Alzheimer's Association
International Conference, Los Angeles, CA
Interviewee (July 2019)
• Utah State doctoral student featured in Alzheimer’s Association International
Conference, Logan, UT
• A Complicated Connection between Sleep and Alzheimer’s risk. Wtop.
https://wtop.com/health-fitness/2019/07/a-complicated-connection-betweensleep-and-alzheimers-risk/
• Sleep Medication Linked to Dementia. AARP.
https://www.aarp.org/health/dementia/info-2019/dementia-sleep-medication.html
• Sleep Medications Tied to Slightly Higher Risk For Alzheimer’s Disease in
Women. Healio. https://www.healio.com/primary-care/womenshealth/news/online/%7B57024686-718d-4dab-9c13-acb01a650a47%7D/sleepmedications-tied-to-slightly-higher-risk-for-alzheimers-disease-in-women
• Utah State University Student Featured in Alzheimer’s Association International
Conference. https://kutv.com/news/local/utah-state-doctoral-student-featured-inalzheimers-association-international-conference
• Sleep Medication and Dementia. The Gilmer Mirror.
www.gilmermirror.com/view/full_story/27661613/article-Sleep-Medications-andDementia?instance=home_news_bullets
• Use of Sleep Meds May Elevate Dementia, Alzheimer’s Risk. MIMS.
https://specialty.mims.com/topic/use-of-sleep-meds-may-elevate-dementia-alzheimer-s-risk?topic-grouper=news
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•

AAIC Roundup: Alzheimer’s, Seizures, Sleep Medications, the LGBT
Community and More. https://www.biospace.com/article/aaic-roundup-alzheimers-seizures-sleep-medication-the-lgbt-community-and-more/

Research Experience
Graduate Research Assistant (August 2015 – Present)
Alzheimer’s Disease and Cognitive Disorders Lab, Utah State University, Logan,
UT.
Supervisor: JoAnn Tschanz, Ph.D.
Completed literature reviews, collaborated with colleagues on manuscripts, conducted
analyses, mentored undergraduate research assistants, and created tables and figures.
Graduate Research Assistant (March 2020-May 2020)
Cache County Family Study, Utah State University, Logan, UT.
Supervisor: JoAnn Tschanz, Ph.D.
Researched neuropsychological batteries and tests to be administered via telehealth.
Graduate Research Assistant (August 2017-August 2018)
Cache County Family Study, Utah State University, Logan, UT.
Supervisor: JoAnn Tschanz, Ph.D.
Created a database in RedCap, assisted in completing IRB protocol, supported the study
running, collected field interview data, and entered data.
Psychometrician and Research Assistant (May 2012-June 2015)
Knight Alzheimer Disease Research Center, Washington University in St. Louis
School of Medicine, St. Louis, MO.
Supervisor: Dr. Jason Hassenstab, Ph.D.
Administered neuropsychological batteries to older adults with and without cognitive
impairment, analyzed collected data, maintained data integrity, and recorded behavioral
observations.
Research Assistant and Research Coordinator (May 2013- June 2015)
Roe Lab: R01 Grant-Factors Impacting Driving in Older Adults, Washington
University in St. Louis School of Medicine, St. Louis, MO.
Supervisor: Dr. Catherine Roe,
Conducted navigational assessments, analyzed, and maintained data, insured compliance
with IRB protocol, collaborated on manuscripts, and worked with an integrated
disciplinary team.
Research Coordinator (May 2014-June 2015)
Dominantly Inherited Frontotemporal Dementia Study, Washington University in
St. Louis School of Medicine, St. Louis, MO.
Supervisor: Nupur Ghoshal, M.D., Ph.D.
Maintained protocol compliance, assisted in grant renewal process, coordinated, and
helped organize the research study.
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Research Assistant (May 2014-June 2015)
Driving Simulator Lab, Washington University in St. Louis School of Medicine, St.
Louis, MO.
Supervisor: David Carr, M.D.
Assisted in grant writing, running participants, conducted data analyses, maintained data
compliance, and assisted in manuscript writing.
Undergraduate Research Assistant (June 2011-August 2011)
Perception and Action Lab, Indiana University, Bloomington, IN
Supervisors: Geoffery Bingham, Ph.D. and Winona Snapp-Childs, Ph.D.
Administered experiments, assisted in data analyses, and conducted experiments with
bimanual rhythmic coordination
Teaching Experience
Guest Lecturer
Abnormal Psychology (Summer 2016, Fall 2016, Summer 2017)
Research Methods (Fall 2015)
Graduate Teaching Assistant
Intellectual Assessment (Spring 2017)
Health Psychology (Spring 2017)
Introductory Psychology (Fall 2015-Spring 2016)
Scientific Thinking and Research Methods (Fall 2015-Spring 2016)
Awards and Honors
Utah State University – Gloria Foster George Scholarship (2017 – 2018)
Utah State University – Annual Kranz Travel Research Award (2015 – Current)
Professional Memberships and Organizations
2019 to Current
American Psychological Association Student Affiliate
APA Division memberships
Division 12 Student Membership
Division 40 Student Membership
Professional Services
Ad hoc reviewer for The American Journal of Geriatrics Society.

